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ABSTRACT 
 
 Prostate cancer (PCa) is a leading cause of morbidity and mortality in the 
United States, and contributes to a significant healthcare burden due to an 
overall lack of curative interventions for advanced-stage disease. Because PCa 
is largely insensitive to cytotoxic chemotherapy, the androgen receptor (AR) has 
long been the primary therapeutic target for the clinical management of locally 
advanced and metastatic PCa. Problematically, targeting AR signaling via 
androgen deprivation or treatment with AR antagonists is associated with 
progression to lethal, castration-resistant prostate cancer (CRPC) via a variety of 
molecular mechanisms that alter AR expression and function. However, CRPC is 
marked by a continued reliance on AR expression and activity. Thus, new modes 
of intervention with ability to durably repress AR activity in advanced CRPC are 
an unmet clinical need. In Chapter 1, we review the problem of castration 
resistance through a new paradigm of genetic rearrangements that produce 
truncated AR variants (ARV), which confer resistance to all current forms of AR-
based PCa therapy. In Chapter 2, we discuss a novel AR inhibitor that directly 
targets the AR NH2-terminal transcriptional activation domain (NTD), but with 
significant off-target effects due to the lack of specificity for the intrinsically 
disordered NTD. In Chapter 3, we characterize the differences in NTD utilization 
between full length AR and ARV. Finally, in Chapter 4, we discuss a brief history 
of AR targeting in PCa, and offer a perspective on how future translational 
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studies can approach the problem of intrinsic disorder in the NTD to develop new 
interventions with more durable and lasting mechanisms of action. 
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 CHAPTER 1 
ANDROGEN RECEPTOR GENE REARRANGEMENTS: NEW PERSPECTIVES 
ON PROSTATE CANCER PROGRESSION 
 
OVERVIEW 
 
 The androgen receptor (AR) is a master regulator transcription factor in 
normal and cancerous prostate cells.  Canonical AR activation requires binding of 
androgen ligand to the AR ligand binding domain, translocation to the nucleus, 
and transcriptional activation of AR target genes.  This regulatory axis is targeted 
for systemic therapy of advanced prostate cancer.  However, a new paradigm for 
AR activation in castration-resistant prostate cancer (CRPC) has emerged 
wherein alternative splicing of AR mRNA promotes synthesis of constitutively 
active AR variants that lack the AR ligand binding domain (LBD).  Recent work 
has indicated that structural alteration of the AR gene locus represents a key 
mechanism by which alterations in AR mRNA splicing arise.  In this review, we 
examine the role of truncated AR variants (ARVs) and their corresponding 
genomic origins in models of prostate cancer progression, as well as the 
challenges they pose to the current standard of prostate cancer therapies 
targeting the AR ligand binding domain.  Since ARVs lack the COOH-terminal 
LBD, the genesis of these AR gene rearrangements and their resulting ARVs 
provides strong rationale for the pursuit of new avenues of therapeutic 
intervention targeted at the AR NH2-terminal domain.  We further suggest that 
1 
genomic events leading to ARV expression could act as novel biomarkers of 
disease progression that may guide the optimal use of current and next-
generation AR-targeted therapy. 
 
INTRODUCTION 
 
 The AR is a 110 kDa protein with a modular domain organization found in 
members of the steroid hormone receptor superfamily [1,2].  The NH2-terminal 
domain (NTD), also referred to as transcriptional activation function (AF)-1, is a 
potent transcriptional activation domain in isolation and is responsible for the 
majority of AR transcriptional activity through the recruitment of diverse co-
regulatory proteins.  The central domain of the AR is the DNA binding domain 
(DBD), which is comprised of two zinc-finger motifs.  The first zinc finger is 
responsible for making direct contact with the DNA major groove of an androgen 
response element (ARE) half-site, while the second zinc finger mediates 
dimerization with a second AR molecule bound to an adjacent ARE half-site [3].  
The DBD is followed by a short, flexible hinge region which contains the bipartite 
nuclear localization signal.  The COOH-terminal domain (CTD) of the AR houses 
both the ligand binding domain (LBD) and a secondary transcriptional activation 
domain termed AF-2. 
 The primary role of the AR is to sense and respond to circulating 
androgens, the most abundant of which are testosterone and 
dihydrotestosterone (DHT) [4,5].  In the absence of ligand stimulation, AR is 
2 
cytoplasmic, bound in a chaperone complex of heat shock proteins and high 
molecular weight immunophilins, which maintains AR protein in an inactive 
conformation with a high affinity for ligand binding [6].  Following ligand binding, 
the AR undergoes a conformational change, causing dissociation of a subset of 
chaperone proteins and exposing the nuclear localization signal in the hinge 
region.  Upon translocation of the AR/DHT complex to the nucleus, the AR DBD 
engages with genomic AREs [7], mediating chromosomal looping and structural 
reorganization of the genome [8-10].  In order for productive gene transcription to 
occur, the AR is reliant on interactions with a wide variety of transcriptional co-
regulators, of which nearly 200 have been identified to date [11].  These 
transcriptional co-regulators form large complexes that result in recruitment of the 
basal transcriptional machinery and a finely-tuned level of androgen-responsive 
gene transcription [12,13].  In healthy prostate tissue, these androgen-responsive 
genes are important for normal prostate architecture, homeostasis, and 
physiological function.  In prostate cancer (PCa), these target genes support 
ongoing proliferation and survival of tumor cells. 
 
Structure and Function of the AR COOH-Terminal Domain 
 The CTD of the AR is the best understood functional domain by virtue of 
its structural homology and regulatory similarities with other steroid receptors 
[14].  The AR gene locus, located at Xq11-12, is approximately 180 kilobases in 
length and consists of eight coding exons separated by intronic segments of 
varying length.  Exon 1 codes for the entire AR NTD, or approximately 60% of the 
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total protein, while exons 2 and 3 code for the two zinc finger domains of the AR 
DBD.  Exons 4-8 are located in close proximity to one another in the AR gene 
locus, and code for the hinge region and CTD/LBD of the AR (Figure 1.1).  
Importantly, all AR-targeted therapeutics currently approved for clinical use 
modulate AR activity by exerting action on this domain [15].  The CTD contains 
11 α-helices that form the binding pocket of the AR LBD, while a twelfth helix  
 
 
Figure 1.1:  Androgen Receptor Functional Domains. The AR possesses a 
modular domain organization common to members of the steroid hormone 
receptor family of nuclear receptor transcription factors. The amino-terminal 
domain (NTD) harbors transcriptional activation units (TAU)-1 and TAU-5. 
Transcriptional activation function (AF)-1a and AF-1b are subdomains of TAU-1. 
The DNA binding domain (DBD) is comprised of two zinc finger motifs (Zn), and a 
flexible hinge (H) region containing the AR nuclear localization signal (NLS). The 
COOH-terminal domain (CTD) harbors the ligand binding domain (LBD), a 
ligand-regulated nuclear export signal (NES), and the protein interaction domains 
AF-2 and binding function (BF)-3. 
 
forms a “kickstand” which locks into place upon androgen binding [16-18].  This 
upswing of helix 12 stabilizes AR binding to DHT and forms the AF-2 protein 
interaction interface [19,20].  AF-2 has been shown to exert transcriptional 
activity in the presence of bound agonist by binding to nuclear receptor (NR)-box 
motifs in coactivators, such as SRC-2 [19], and is also capable of mediating 
intramolecular interaction with FxxLF or WxxLF motifs in the AR NTD [21].  
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Furthermore, the CTD contains a ligand-regulated nuclear export signal which is 
dominant over the AR nuclear localization signal but is inhibited by ligand binding 
[22]. 
 Recent work has provided evidence for a second protein interaction 
domain within the CTD, termed binding function (BF)-3, which communicates 
allosterically with AF-2 [23,24].  Interestingly, a host of mutations identified in both 
PCa and androgen insensitivity syndrome map to BF-3, supporting the concept 
that this domain may play an important role in allosteric regulation of AR function 
[25].  Another recent study provided evidence that FKBP52, a co-chaperone 
protein critical for maintaining AR in a conformation competent for ligand binding, 
may interact with AR through the BF-3 domain [26].  Importantly, these critical 
AF-2/BF-3 mediated functions are amenable to targeting with small molecules 
[23,26-28] which could potentially lead to new avenues of AR-targeted therapy. 
 
Therapeutic Targeting of the COOH-Terminal Domain in Prostate Cancer 
 PCa is the most frequently diagnosed male cancer and second leading 
cause of cancer deaths [29].  For tumors that are relapsed, locally advanced, 
and/or metastatic, the current standard of care is androgen deprivation therapy 
(ADT), achieved by suppression of AR signaling through the use of AR 
antagonists such as bicalutamide or flutamide, or by preventing production of 
testosterone by the testes using gonadotropin releasing hormone agonists such 
as leuprolide [15].  ADT initially provides a robust therapeutic benefit by blocking 
tumor cell proliferation and inducing apoptosis, resulting in clinical regression.  
5 
Invariably, however, AR signaling is eventually reactivated via diverse 
mechanisms including AR amplification and/or AR protein overexpression, gain of 
function AR mutations [30,31], enhanced uptake and conversion of adrenal 
androgens, or de novo androgen synthesis by tumor cells [32]. These 
mechanisms have been reviewed in detail elsewhere [33-35]. These molecular 
events mark a transition from the initial androgen-dependent PCa to a lethal form 
of the disease, referred to as “castration-resistant PCa” (CRPC).  Enzalutamide 
(formerly MDV3100), which is an AR antagonist that excludes AR from the 
nucleus, and abiraterone acetate, which blocks peripheral androgen synthesis by 
inhibiting CYP17, were developed to address these mechanisms of disease 
progression [36,37]. In Phase III trials, abiraterone and enzalutamide increased 
overall survival CRPC patients by 3.9 and 4.8 months, respectively [38,39].  
Clinical trials have demonstrated that both drugs provide significant therapeutic 
benefit to a high proportion of patients [38-40], but a subset of patients continue 
to experience disease progression, either through acquired resistance or through 
de novo insensitivity prior to treatment. Currently, it is of major interest to identify 
mechanisms that may drive these types of resistance to help develop next-
generation AR-targeted therapies. Importantly, unlike other steroid hormone 
receptors in which AF-2 is the dominant transactivation domain, the AR NTD is 
responsible for the majority of AR transactivation [19]. Therefore, recent work 
describing the discovery and characterization of constitutively active AR splice 
variants which lack the CTD regulatory domain have generated significant 
interest, as these species may be capable of restoring AR signaling in PCa 
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tissues following ADT through a mechanism of constitutive AR NTD 
transcriptional activity.   
 
CONSTITUTIVELY ACTIVE AR SPLICE VARIANTS PROMOTE CASTRATION 
RESISTANCE IN PROSTATE TUMORS 
 
 Splice variants of the AR have been recognized for over two decades in 
the context of loss-of-function splicing alterations in androgen insensitivity 
syndrome, which is a topic that has been reviewed in detail elsewhere [41].  The 
first gain-of-function AR splice variant (ARV) was identified in 22Rv1 cells due to 
the presence of a smaller, 75-80 kDa AR immunoreactive species on western 
blot that was initially thought to be a proteolytic degradation fragment of full 
length AR [42].  This AR subspecies was shown to lack a ligand binding domain 
and was constitutively active in both the presence and absence of androgen.  
Similarly, a subsequently identified Q640Stop mutation resulted in premature 
truncation and constitutive AR signaling in bone metastases from a patient who 
relapsed following ADT with luprorelin and flutamide [43]. It was initially 
postulated that the smaller band observed in the 22Rv1 cell line resulted from 
calpain-mediated cleavage of full length AR at a consensus calpain recognition 
site in the AR hinge region [44]. However, later work demonstrated that RNA 
interference (RNAi) targeted against AR exon 7 (Figure 1.1) had no effect on 
expression levels of the smaller species, despite robust ablation of full length AR. 
Conversely, RNAi targeted against AR exon 1 led to ablation of both the full 
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length and the truncated species [45]. These data strongly suggested that the 
truncated ARV was not a product of full length AR mRNA or protein, but instead 
derived from an alternate mRNA species.  The ability to differentially target full-
length vs. truncated ARV species with discrete RNAi reagents further revealed 
that the constitutive activity of the truncated ARV was the driving force behind the 
androgen independent proliferation of 22Rv1 cells. 
 Since their initial identification, nearly a dozen different ARV mRNA 
species have been identified in PCa cell lines, xenografts, and clinical samples 
[41].  ARVs arise as a result of the incorporation of alternative, or cryptic, exons 
coded for in the AR gene locus [45-48], or through an exon skipping mechanism 
in which non-contiguous AR exons are spliced together [49]. Characterization of 
these novel ARV mRNAs has revealed multiple alternative, or “cryptic” exons in 
the AR locus, most of which flank AR exon 3. For example, alternative exon 2b 
(also termed cryptic exon 4, or “CE4”) is located upstream of exon 3, whereas 
many others are within AR intron 3 (CE1, CE2, CE3, CE5, and exon 3'). The 
products of these splicing aberrations generally incorporate canonical AR exons 
1-3, which code for the AR NTD as well as the DBD.  These three exons appear 
to form the minimum requirement for a transcriptionally active ARV [50].  
However, ARVs differ in their utilization of exons 4-8, with most ARVs 
incorporating one of the seven currently identified cryptic exons coded for by the 
AR locus [41].  Problematically, multiple naming systems have been proposed to 
refer to the various ARVs.  For example, the ARV encoded by contiguously 
spliced exons 1, 2, 3, and 2b has been alternately named AR-V4 [47], AR5 [46], 
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and ARV6 [48].  Therefore, for the purposes of this review, we will refer to the 
variants by their exon composition, e.g. AR 1/2/3/2b, to alleviate confusion.  To 
date, only three ARV transcripts have been mechanistically investigated in cell 
lines, xenografts, or clinical samples: AR 1/2/3/CE3, AR 1/2/3/2b, and AR 
1/2/3/4/8. 
 The most studied and currently best characterized ARV is coded for by AR 
exons 1/2/3/CE3, alternatively termed AR-V7 and AR3 [46,47].  AR 1/2/3/CE3 
has been shown to be expressed at the mRNA and protein level in normal and 
cancerous prostate tissue, multiple commonly used PCa cell lines, and human 
tumor xenografts.  Expression of this isoform was also demonstrated to be 
increased in locally recurrent and metastatic castration resistant PCa tissue 
compared to prostatectomy specimens from hormone naïve men [46].  A 
separate study found that 1/2/3/CE3 mRNA expression levels in prostatectomy 
specimens could predict the likelihood of biochemical recurrence after surgery 
[47].  Biochemically, 1/2/3/CE3 was shown to function as a constitutively active 
transcription factor independent of androgen ligand [46].  However, the exact 
transcriptional program mediated by this variant may differ slightly from full-length 
AR.  In one study, transient transfection of LNCaP cells with an AR 1/2/3/CE3 
expression vector was shown to effect a strikingly similar transcriptional program 
compared with ligand-activated full length AR [47].  On the other hand, a second 
study using targeted siRNA knockdown of endogenous full length AR versus 
1/2/3/CE3 demonstrated that the CE3 isoform activated Akt expression, whereas 
full-length AR did not [47].  More recently, Hu and colleagues [51] have reported 
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a unique role for AR 1/2/3/CE3 in the activation of M-phase specific cell cycle 
genes.  For example, whereas full-length AR target genes appeared to be largely 
associated with pathways important for biosynthesis and metabolism, the 
1/2/3/CE3 variant was able to activate transcription of pro-mitotic cell cycle 
regulators such as UBE2C, CDCA5, ZWINT, TPX2, and CDC25C.  Taken 
together, these data strongly support a role for the AR 1/2/3/CE3 splice variant as 
a constitutively active AR isoform with significant clinical implications for biology 
and treatment of castration resistant PCa tumors. 
 The AR 1/2/2b and AR 1/2/3/2b mRNA variants were initially identified by 
5' RACE experiments in the 22Rv1 cell line [45].  Specific knockdown of these 
ARVs using an exon 2b-targeted siRNA resulted in an expected reduction in the 
truncated 75-80 kDa AR species, suggesting that one or both of the 1/2/2b and 
1/2/3/2b mRNAs were translated.  However, our laboratory recently developed an 
antibody specific to the COOH-terminal extension encoded by AR exon 2b, which 
revealed that only the AR 1/2/3/2b variant is productively translated to functional 
protein in 22Rv1 cells [50].  Importantly, siRNA knockdown of AR 1/2/3/2b 
significantly reduced the ability of 22Rv1 cells to proliferate in the absence of 
androgen, but had no effect on androgen dependent proliferation, supporting a 
role for this ARV as a driver of castration resistance in 22Rv1 cells [45].   
 Finally, AR 1/2/3/4/8 was shown to arise through the skipping of exons 5-7 
in the mRNA transcript [49].  This exon skipping event places exon 8 out-of-
frame, resulting in formation of a premature translation termination codon in exon 
8.  This variant, originally named ARv567es, is expressed at the mRNA level in a 
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wide range of normal and cancerous prostate tissues, although protein 
expression has not yet been confirmed using variant-specific antibodies.  Sun 
and colleagues also demonstrated that AR 1/2/3/4/8 mRNA is expressed 
endogenously in the LuCaP 86.2 and 136 xenografts, and inferred that this 
protein was expressed endogenously due to its molecular weight.  Interestingly, 
upon castration, mRNA levels of AR 1/2/3/4/8 increased in these xenografts 
compared with intact hosts.  When expressed ectopically in LNCaP cells, AR 
1/2/3/4/8 displayed constitutive transcriptional activity and could interact directly 
with full length AR, resulting in enhanced ligand dependent and -independent 
activity of the full length receptor in these cells.  A later study by Hu and 
colleagues demonstrated that a novel ninth exon, located downstream of AR 
exon 8, was incorporated into the mRNA transcript of this AR 1/2/3/4/8 variant in 
VCaP cells [51].  However, because incorporation of exon 9 does not affect the 
premature translation stop codon in exon 8, this exon simply alters the 3’ 
untranslated region of this mRNA.  Therefore, AR 1/2/3/4/8/9 mRNA codes for 
exactly the same protein as AR 1/2/3/4/8 mRNA, and thus it is not surprising that 
this variant displayed constitutive, ligand independent activity in promoter-
reporter assays.  Interestingly, in this study, the strength of AR 1/2/3/4/8/9 
transcriptional activity appeared to depend on which cell line it was tested in, with 
higher activity apparent in PC-3 vs. LNCaP PCa cell lines. 
 Although all active gain of function ARVs identified to date consist of the 
AR NTD and DBD, they harbor unique COOH-terminal extensions encoded by 
the various exons that can be spliced into the 3’ mRNA termini of AR variant 
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transcripts.  This has been proposed to bear significant implications for ARV 
biochemistry because the bipartite nuclear localization signal (NLS), 
RKx10RKLKK, spans the exon 3-4 junction in wild type AR [52].  Therefore, since 
most of the ARV mRNAs identified to date do not harbor exon 4, the bipartite 
NLS would be disrupted in these variants.  However, recent work has 
demonstrated that the AR NTD/DBD core displays a high level of constitutive 
nuclear localization in the absence of ligand that is independent of both HSP90 
and the nuclear import adapter protein importin-β, resulting in transcriptional 
activation of endogenous AR targets [50].  Moreover, this study demonstrated 
that differences in ARV transcriptional activity that have been observed are 
promoter-dependent phenomena as opposed to arising from differential rates of 
nuclear access.   
 
GENOMIC REARRANGEMENTS PROMOTE DISEASE PROGRESSION AT 
MULTIPLE STAGES OF PROSTATE CANCER DEVELOPMENT 
 
Gene Rearrangements Prior to ADT: From PIN to PCa and Beyond 
 Beginning with the discovery of recurrent Ets-family gene rearrangements 
in 2005 [53], it has become increasingly clear that structural alterations are 
frequent events in the PCa genome and underpin many aspects of tumor biology 
and disease progression.  These events include the highly prevalent TMPRSS2-
Ets family of gene fusions [53] as well as fusions involving Raf family members 
[54].  A number of other rearrangements have also been identified in primary 
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prostate tumors, which may represent novel mechanisms for driving tumor 
invasiveness, proliferation/survival, and anchorage-independent growth in PCa 
[55,56].  These gene rearrangements have been reviewed in detail elsewhere 
[57].  More recently, chromosomal alterations involving the PTEN locus have 
been shown to cooperate with allelic loss to drive PCa progression [[58].  
Interestingly, this mechanism of PTEN inactivation, as well as the 
rearrangements reported by Pflueger et al. [56], was highly correlated with 
underlying TMPRSS2-ERG chromosomal rearrangement, supporting a role for 
Ets family rearrangements as a genome-destabilizing event early in prostate 
tumorigenesis.  This may also explain the observation that patients with fusion-
positive PCa experience more aggressive and lethal disease compared with 
fusion-negative cases [59,60], though a number of studies have reported that 
TMPRSS2:Ets rearrangement may alternatively correlate with low Gleason grade 
[61], favorable prognosis [62], or may not be predictive of disease outcome at all 
[63].  Regardless, clinical samples from men with metastatic castration-recurrent 
PCa exhibit a wide range of mutations, deletions, and rearrangements as 
determined by exome sequencing [64].  Overall, these genomic rearrangements 
have been shown to be associated with and predictive of PCa genesis and/or 
progression, such that molecular subtyping of based on these criteria may result 
in improvements in patient management and/or clinical trial designs [57]. 
 
Rearrangements of the AR Locus: a New Paradigm for ARV Expression and 
Activity Following ADT? 
13 
 These recent whole genome studies have also supported the long-held 
fundamental concept that the AR signaling axis is a critical master regulator in 
PCa.  Foremost, this axis has been shown to be the most frequently-altered 
pathway in hormone-naïve PCa, and 100% of castration-resistant PCa 
metastases display genomic and/or mRNA expression alterations in this pathway, 
most frequently in the AR gene itself [66].  The observation that AR exon 2b is 
incorporated into the 1/2/3/2b transcript downstream of exon 3 in 22Rv1 cells, 
despite the fact that 2b is located 5' of exon 3 in the normal reference genome 
[45,47] (Figure 1.2), raised an intriguing question: what is the molecular basis for 
this splicing pattern?  One clue came from the observation that the full-length AR 
in 22Rv1 cells is slightly larger due to an extra zinc finger in the DBD encoded by 
tandem duplication of AR exon 3.  Interestingly, in addition to these unanticipated 
splicing patterns, it was demonstrated that the 22Rv1 cell line exhibits 
significantly increased mRNA expression of the AR 1/2/3/CE3 variant [65].  In the 
same study, the androgen-dependent CWR22Pc cell line, which was derived 
from the same original CWR22 xenograft model as 22Rv1, was found by 
quantitative RT-PCR analysis to express extremely low but detectable transcript 
expression of these ARVs.  These observations suggested that the observed 
splicing patterns may not be true “alternative splicing” events in 22Rv1 cells, but 
may instead be due to an underlying alteration in AR gene structure.  Indeed, 
interrogation of AR gene structure demonstrated that the region harboring exon 
2b, 3, and CE1-3 was present in the genome at two-fold higher copy number in 
castration-recurrent 22Rv1 cells, but not CWR22Pc, suggesting the presence of 
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a tandem duplication [65].  More detailed analysis confirmed that a ~35kb 
segment, comprised of exon 3 and its flanking cryptic exons, was involved in a 
tandem duplication event within 22Rv1 cells (Figure 1.2).  Importantly, long term 
culture of the lineage-related CWR22Pc cell line in the absence of androgen 
resulted in the outgrowth of a castration resistant population of cells that 
harbored the exact same break fusion junction and repair signature as 22Rv1, 
and displayed increased expression of truncated ARVs mRNAs and proteins 
 
 
Figure 1.2:  AR Genomic Alterations and Altered Splicing Patterns Leading 
to ARV Expression.  The 180 kb androgen receptor gene locus harbors eight 
canonical exons (black vertical hashes) that code for the wild type AR mRNA and 
protein (black boxes).  Seven alternative, or cryptic, exons have also been 
identified (gray vertical hashes) that can be incorporated into the AR transcript 
upon activation of alternative splicing pathways (gray borders/boxes).  Four 
discrete AR gene rearrangements or mutations, depicted as dashed black lines, 
have been shown to disrupt AR splicing and favor the expression of AR variants 
in PCa cell lines and xenografts. 
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including 1/2/3/2b and 1/2/3/CE3.  These data indicate that a subset of cells 
within the original CWR22 tumor harbor this rearrangement and are driven by 
constitutive, ligand-independent ARV activity prior to androgen deprivation.  In 
this cell line, ADT simply results in selective outgrowth of these ARV-driven cells 
harboring the 35kb tandem duplication.  Importantly, complex patterns of AR 
gene copy imbalance were also observed in metastatic CRPC samples, but not 
in hormone-naïve primary tumors [65], suggesting that generation of 
constitutively active ARV through genomic rearrangements may be a recurring 
theme in human disease progression. 
 Interestingly, ARV have also been described in the mouse PCa cell line 
Myc-CaP [66], in which the AR is amplified through genomic copy number gain.  
Mouse AR (mAR)-V2 was shown to result from splicing of exons 1-3 together 
with a novel cryptic exon located ~250 kb downstream of the AR gene locus.  
Perhaps even more compelling, a second ARV termed mAR-V4 was generated 
by splicing of exons 1-4 and a novel cryptic exon located nearly 1 Mb upstream 
of the AR transcriptional start site.  Whereas mAR-V2 showed little activity in 
functional assays, mAR-V4 was constitutively active and localized to the nucleus, 
similar to ARVs identified in human cell lines and tissues.  Though the molecular 
basis for splicing of mAR-V4 was not addressed in this study, it is likely 
contingent upon the known amplification of the AR gene in Myc-CaP cells.  
Following this rearrangement of the AR gene, the V4 cryptic exon could be 
situated downstream of the AR open reading frame, thus accounting for the 
incorporation of the V4 exon at the 3’ terminus of the transcript. 
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 Further investigation of genomic copy number imbalance in additional 
models of CRPC progression has confirmed AR gene rearrangements as an 
important mechanism involved in the generation of constitutively active ARVs 
[67].  Multiplex ligation dependent probe assays (MLPA) were employed to query 
the copy number of AR exons in a variety of PCa cell lines and tissues.  
Interestingly, LuCaP 86.2 cells displayed reduced copy number of AR exons 5-7, 
which was shown subsequently to result from an 8.5kb intragenic deletion of this 
genomic segment (Figure 1.2).  Clearly, deletion of AR exons 5-7 provides an 
attractive mechanistic explanation for synthesis of the AR 1/2/3/4/8 variant in this 
xenograft model [49].  Interestingly, deletion of exons 5-7 prevents synthesis of 
full-length AR, indicating that this CRPC tumor would no longer be driven by 
androgen/AR signaling, but rather depends exclusively on the AR 1/2/3/4/8 
variant for ongoing growth and survival. 
 An additional model of CRPC that has been shown to express high levels 
of truncated ARVs is the CWR-R1 cell line.  To determine the basis for the 
splicing alterations in this model, Illumina paired-end massively parallel 
sequencing was employed to determine the sequence and structure of the AR 
locus [67].  This approach detected copy number loss spanning a 48 kb region of 
AR intron 1 (Figure 1.2), which was supported by MLPA data querying copy 
number throughout AR intronic sequences.  Interestingly, this deletion was 
initially observed only within a subpopulation of CWR-R1 cells.  However, long 
term culture of CWR-R1 cells in androgen-depleted growth medium resulted in 
the outgrowth of the deletion-positive population.  Importantly, the outgrowth of 
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this subpopulation was accompanied by a corresponding increase in the protein 
expression of the constitutively active AR 1/2/3/CE3 variant.  This finding 
supports the possibility that within at least some prostate tumors, subpopulations 
of ARV-driven cells with underlying rearrangements in the AR gene may exist 
prior to administration of AR-targeted therapies and, by virtue of constitutively 
active ARV expression, be able to overcome any drug in the current arsenal of 
AR-based therapies to repopulate the tumor.  Based on the finding that ARV 
expression is an important feature of CRPC progression [46,47,49,68,69] and 
these recent data demonstrating AR gene rearrangements as a mechanism for 
altered AR splicing [65,67], it is possible that AR gene rearrangements may 
represent a new class of genomic markers with predictive and/or prognostic 
value in CRPC.   
 
STRUCTURE AND FUNCTION OF THE AR NTD 
 
 The role of ARVs in clinical PCa and castration resistance highlights the 
need for a greater understanding of NTD structure and function to aid in the 
design of AR-targeted therapeutics that do not require an intact AR LBD.  The 
principal role of the NTD is to serve as a docking site for AR transcriptional co-
regulators [70], and it is well established that the NTD is the predominant 
transcriptional activation domain of the AR [2,19,71].  This stands in contrast to 
other steroid hormone receptors, in which the CTD harbors the primary 
transcriptional activation domain [19].  The NTD is divided into two primary 
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transcriptional activation units (TAUs) termed TAU-1 and TAU-5, which have 
been shown to have distinct roles in AR-mediated transcription [2,72] (Figure 
1.1).  The TAU-5 domain maps to amino acids 361-490 of the AR NTD, and has 
been shown to promote AR activity specifically under conditions of low/no 
androgens [72,73].  Deletion of TAU-5 causes near-complete loss of AR function 
in the absence of DHT in both androgen dependent LNCaP [72] and castration 
resistant C4-2 cells [73].  Further work mapped TAU-5 activity to a conserved 
Trp-His-Thr-Leu-Phe (WHTLF) motif, and deletion or mutation of the hydrophobic 
W/L/F residues to alanine significantly inhibited androgen independent AR 
activity [71].  Interestingly, however, a recurring W435L mutation found in 
metastatic PCa tissue from patients relapsing after ADT was shown to increase 
ligand-dependent AR transcriptional activity, possibly through stabilization of an 
N/C intramolecular interaction between this domain and the AF-2 region [31]. 
 The other major domain within the NTD, TAU-1, maps to amino acids 101-
360 and houses two smaller subdomains, known as activation function (AF)-1a 
(amino acids 101-211) and AF-1b (amino acids 252-360).  Deletion of either of 
the AF-1 sub domains causes complete loss of AR transcriptional activity in both 
androgen dependent LNCaP cells as well as castration resistant C4-2 cells, 
whereas deletion of the internal spacer region between AF-1a and -1b actually 
enhances AR transcription [73].  The transcriptional activity of TAU1 has 
traditionally been ascribed to an LxxLL-like motif, LKDIL, located within AF-1a 
[69].  Deletion or mutation of this sequence causes significant loss of AR activity, 
similar to deletion of the entire AF-1a fragment [70].  Intriguingly, the LKDIL motif 
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overlaps an Lx7LL motif described by Zhu and colleagues [74], which is critical for 
mediating interaction with the transcriptional co-repressor NCoR and its binding 
partner TAB2.  When TAB2 was phosphorylated by MEKK1, the NCoR/TAB2 
complex was released, resulting in AR de-repression.   However, no 
transcriptional co-activators have yet been identified that specifically bind to the 
LKDIL motif following co-repressor dissociation [75].  Furthermore, attributing 
TAU-1 activity exclusively to LKDIL does not account for the transcriptional loss 
observed upon deletion of AF-1b, suggesting that other elements within the TAU-
1 domain may be important to the activity of this region [73].   
 
Therapeutic Targeting of the AR NTD 
 The AR represents a nearly ideal drug target, in that pharmacologic 
targeting of the AR signaling axis produces profound results on prostate tumor 
biology with relatively minimal toxic side effects.  While therapies that require an 
intact AR LBD have proven effective in treating PCa, mounting evidence 
suggests that the CTD may be ultimately dispensable for AR function in the 
context of CRPC.  Observations of CTD-truncated ARVs, which function as 
potent, constitutively active transcription factors independent of the CTD, suggest 
that the NTD itself could be an alternative target for inhibition of AR 
transcriptional activity.  Despite significant progress in defining the structural and 
functional composition of the AR NTD with the goal of therapeutic targeting, one 
principal challenge is the inherent flexibility and lack of tertiary structure 
throughout the NTD [76].  These structural characteristics are likely to be of 
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fundamental importance to the transcriptional activity of the AR, but they have 
also proven to be a major obstacle to crystallographic analysis of AR structure 
and subsequent intelligent drug design.  Nonetheless, two promising classes of 
drugs have recently been identified that seem to interact specifically with the 
NTD to mediate its inhibition.  EPI-001 is a chlorinated bisphenol A diglycidyl 
ether (BADGE) identified in a high-throughput screen for compounds that could 
inhibit AR NTD activity.  EPI-001 was demonstrated to function by preventing 
binding of the CBP/p300 histone acetyltransferase to the AR NTD, thereby 
preventing AR activity at target gene enhancers and preventing outgrowth of 
castration recurrent tumors in a xenograft model [77,78]. A similar drug screen for 
compounds isolated from the marine sponge Niphates digitalis identified a class 
of drugs termed Niphatenones [79], which were shown by click chemistry to 
covalently bind to an unknown portion of the AR NTD. This binding was shown to 
rely on a glycerol ether substructure and an extended saturated alkyl chain 
flanking the central ketone of Niphatenone B, which was shown to mediate 
growth inhibition in AR-expressing LNCaP cells but not AR-negative PC3 cells.  
These data suggest that the effect is AR specific, though no studies were 
performed to rule out effects on other steroid hormone receptors. Importantly, 
these compounds have not yet been tested against cell or xenograft models 
bearing truncated ARV, a critical experiment that will likely determine their impact 
and usefulness in the long-term maintenance of PCa. Taken together, however, 
the recent identification of these AR NTD inhibitors provides strong proof of 
principle that the NTD remains a vital and viable therapeutic target, and may be a 
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key to containing the progression of late-stage PCa. 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 The discovery and characterization of ARVs has indicated that tumors 
driven by these species may represent a clinically relevant molecular subtype of 
CRPC that may require different therapeutic intervention than tumors only 
harboring full length AR. Whereas Ets family gene rearrangements have been 
proposed as a specific biomarker of PCa, high levels of ARV expression may 
serve as a marker of true androgen independence: ARV-positive tumors are 
highly unlikely to respond to any currently available antiandrogens or ADT 
strategies. Even next-generation AR targeted therapies, including the potent 
antiandrogen enzalutamide and induction of a super-castrate state with the 
CYP17 inhibitor abiraterone, fail to provide clinical benefit in a significant fraction 
of patients. It is tempting to hypothesize that these patients might progress due to 
AR gene rearrangements and/or expression of ARVs that lack the domain 
targeted by these new drugs. Used in conjunction with the classification schema 
suggested by Rubin and colleagues [57], ARV status could serve as an additional 
biomarker to inform the optimal use of current and next-generation ADT, as well 
as non-AR based therapies, in the treatment of PCa. 
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CHAPTER 2 
EPI-001 IS A SELECTIVE PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTOR-GAMMA MODULATOR WITH INHIBITORY EFFECTS ON AR 
EXPRESSION AND ACTIVITY IN PROSTATE CANCER 
 
 
OVERVIEW 
 
 The androgen receptor (AR) is a driver of prostate cancer (PCa) cell 
growth and disease progression. Therapies for advanced PCa exploit AR 
dependence by blocking the production or action of androgens, but these 
interventions inevitably fail via multiple mechanisms including mutation or 
deletion of the AR ligand binding domain (LBD). Thus, the development of new 
inhibitors which act through non-LBD interfaces is an unmet clinical need.  EPI-
001 is a bisphenol A-derived compound shown to bind covalently and inhibit the 
AR NH2-terminal domain (NTD). Here, we demonstrate that EPI-001 has general 
thiol alkylating activity, resulting in multilevel inhibitory effects on AR in PCa cell 
lines and tissues. At least one secondary mechanism of action associated with 
AR inhibition was found to be selective modulation of peroxisome proliferator 
activated receptor-gamma (PPARγ). These multi-level effects of EPI-001 resulted 
in inhibition of transcriptional activation units (TAUs) 1 and 5 of the AR NTD, and 
reduced AR expression. EPI-001 inhibited growth of AR-positive and AR-negative 
PCa cell lines, with the highest sensitivity observed in LNCaP cells. Overall, this 
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study provides new mechanistic insights to the chemical biology of EPI-001, and 
raises key issues regarding the use of covalent inhibitors of the intrinsically 
unstructured AR NTD. 
 
INTRODUCTION 
 
 Prostate cancer (PCa) is the most commonly diagnosed male cancer in 
the US with approximately 233,000 new cases and 30,000 deaths predicted in 
2014 [29].  Normal and cancerous prostate tissues are dependent on activation 
of the androgen receptor (AR) to support cell proliferation and survival [81,82]. 
Thus, inhibiting AR activation serves as the basis for treating metastatic disease 
[83]. However, these therapies ultimately fail via a variety of molecular 
mechanisms [84]. Importantly, these castration-resistant PCa (CRPC) tumors 
remain AR-dependent, as evidenced by the increased overall survival of patients 
treated with second-generation androgen deprivation therapies enzalutamide 
[39,85,86] and abiraterone [87]. Despite these advances, resistance to 
enzalutamide and abiraterone is frequent and several AR re-activation 
mechanisms have been reported as likely drivers [88-92].  Therefore, 
development of novel AR-targeted therapeutics that are active in CRPC remains 
an important area of investigation [93]. 
 
 The AR is a modular steroid hormone receptor transcription factor with the 
primary transcriptional activation function mapping to Transcriptional Activation 
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Units (TAU)1 and TAU5 in the intrinsically unstructured AR NH2-terminal domain 
(NTD) [2,94]. The functional importance of these domains is evidenced by the 
expression of AR splice variant proteins in CRPC, which are constitutively active 
AR species composed of the AR NTD and central DNA binding domain (DBD), 
but lacking the regulatory LBD [80,95].  This highlights the clinical need for new 
therapeutics that exert action through non-LBD interfaces on the AR protein 
[80,95]. The Bisphenol A Diglicydyl Ether (BADGE) derivative, EPI-001, was 
identified as a specific inhibitor of the AR that bound covalently to an 
undetermined structural motif in the AR NTD and inhibited the growth of 
androgen sensitive PCa and CRPC cells in vitro and in vivo [77,78]. Here, we 
interrogated the mechanism by which EPI-001 inhibits the AR NTD. We show 
that EPI-001 is a general thiol modifier with myriad effects on AR expression and 
activity, as well as selective modulation of the peroxisome proliferator-activated 
receptor-gamma (PPARγ). Overall, this study provides novel insights to EPI-001 
chemical biology that will be critical for ongoing development of AR NTD 
inhibitors.  
 
RESULTS 
 
EPI-001 Inhibits Transcriptional Activity of Both AR TAU1 and TAU5 
 
 LNCaP cells were treated with a range of EPI-001 concentrations to 
identify doses that effectively inhibited AR-responsive luciferase reporters.  
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 Figure 2.1: LNCaP cells were transfected with the indicated reporter constructs 
and cultured for 24 h in androgen-depleted medium. Cells were then transferred 
to serum-free medium supplemented with 1 nM Mibolerone or vehicle control, 
and treated 24 h with increasing concentrations of EPI-001 as indicated. Bars 
represent mean +/- SE for n = 6 samples from two biological replicates. 
 
Contrary to previous reports showing that 10 μM EPI-001 achieved robust AR 
inhibition [77], we observed that a 50 μM dose of EPI-001 was required to inhibit 
AR activation by the synthetic androgen mibolerone (Figure 2.1). To identify the 
specific AR TAU through which 50 μM EPI-001 inhibited AR activity, we 
performed promoter tethering assays with an ARGal4 hybrid wherein the AR DBD 
had been replaced with the yeast Gal4 DBD (Figure 2.2A, construct 2). As a 
negative control, we used bisphenol A bis[2,3-dihydroxypropyl] ether (BABDHE), 
as it is structurally similar to EPI-001 but contains a diol instead of a reactive 
chlorohydrin (Figure 2.2B) [78]. EPI-001 inhibited ligand-dependent ARGal4 
transcriptional activity in LNCaP cells (Figures 2.3A and 2.3B), as well as 
aberrant, ligand-independent AR-Gal4 transcriptional activity in the CRPC C4-2 
cell line (Figure 2.3B). Deletion of TAU5 from ARGal4 increased androgen-
dependent ARGal4 activity and decreased androgen-independent ARGal4 activity, 
consistent with previous reports [73], but this deletion did not affect 
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 Figure 2.2: (A) Schematic of Gal4-based AR expression constructs. (B) 
Chemical structures of EPI-001 and BABDHE. 
 
responsiveness to EPI-001 (Figure 2.3B). Conversely, deletion of TAU1 
decreased androgen-dependent and -independent modes of ARGal4 
transcriptional activity in LNCaP and C4-2 cells (Figure 2.3B). This precluded 
evaluation of EPI-001 effects on TAU1 in LNCaP, but residual androgen-
independent ARGal4 transcriptional activity in C4-2 cells remained responsive to 
EPI-001 (Figure 2.3B). To test the responsiveness of discrete AR TAUs to EPI-
001 directly, we tethered the entire AR NTD, or TAU1 or TAU5 fragments to the  
 
 
Figure 2.3: LNCaP and C4-2 cells were transfected with constructs shown in 
panel A along with sPSAGal4-luciferase and treated as indicated (V: Vehicle 
control; E: EPI-001 50 μM; B: BABDHE 50 μM). (A) LNCaP lysates treated in the 
absence of serum and androgen were subjected to western blot. (B) LNCaP and 
C4-2 protein lysates were subjected to luciferase assay. Bars depict mean +/- 
standard error (C4-2: n = 4 from 2 independent duplicate experiments; LNCaP: 
n=5 from 2 independent duplicate/triplicate experiments). = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001. 
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Figure 2.4: (A) PC-3 and (B) LNCaP cells were transfected with the indicated 
NTD domains tethered to Gal4 DBD (see Fig. 1A for schematic) and the Gal4-
responsive pG5-Luciferase reporter, then treated overnight with 50 μM EPI-001, 
50 μM BABDHE, or vehicle control.  (C) PC-3 cells were transfected with the 
indicated constructs corresponding to panel (A) and treated overnight with 50 μM 
EPI-001 or vehicle control. Lysates were subjected to western blot. Bars 
represent mean +/- SE for n = 6 samples from two separate experiments. 
 
Gal4 DBD (Figure 2.2A, constructs 5-7). In all cell lines tested, EPI-001 inhibited 
transcriptional activity of the NTD-Gal4 hybrid (Figures 2.4 and 2.5). The Gal4- 
TAU1 and Gal4-TAU5 fusion proteins displayed cell line-specific transcriptional 
activity, due to inefficient expression in PCa cell lines (Figures 2.4 and 2.5). In 
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 Figure 2.5: 293T cells were transfected with the constructs shown in panel A 
along with pG5-luciferase and treated with the indicated drugs. Protein lysates 
were subjected to (A) western blot or (B) luciferase assay. Bars depict mean +/- 
standard error (n=6 from 2 independent triplicate experiments). * = p < 0.05, ** = 
p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
 
293T fibroblasts, transcriptional activity of the Gal4-TAU1 and –TAU5 constructs 
was potently inhibited by EPI-001 (Figure 2.5). These data agree with previous 
reports of direct AR inhibition by EPI-001, but extend this knowledge by 
demonstrating the effects could not be mapped to a discrete AR TAU. This 
indicates two possible scenarios: 1) EPI-001 binds specifically to both TAU1 and 
TAU5, or 2) EPI-001 has a more general effect on transcriptional activities of 
TAU1 and TAU5. 
 
EPI-001 inhibits endogenous AR mRNA and protein expression. 
 Interestingly, we observed that endogenous AR protein levels were 
consistently repressed in PCa cell lines treated with EPI-001 (Figure 2.3).  To 
explore this phenomenon, we tested the effect of EPI-001 on AR protein levels in 
a panel of androgen sensitive PCa (Figure 2.6A) and CRPC (Figure 2.6B) cell 
lines. In all cell lines, EPI-001 treatment decreased expression of full-length AR 
protein to varying degrees (Figures 2.6A and B). AR protein loss occurred  
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 Figure 2.6: (A) Androgen sensitive PCa and (B) CRPC cell lines were treated 
overnight in serum-free medium with 1 nM DHT and/or 50 μM EPI-001 as 
indicated, and analyzed by western blot. Densitometry data for both full length 
(AR-fl) and truncated variant (AR-v) isoforms are provided. 
  
between 8 and 16 hours of treatment and was independent of the proteasome 
(Figure 2.7). In line with this, AR mRNA expression in LNCaP and C4-2 cells was 
reduced in response to EPI-001 at time points preceding the observed decreases 
in AR protein expression (Figure 2.8). EPI-001 also inhibited the mRNA 
expression of AR and the AR target gene PSA in LAPC4 cells (Figure 2.9A). EPI-
001 treatment also decreased expression of truncated AR variant (AR-v) proteins 
expressed in the CRPC 22Rv1 cell line (Figure 2.6B). Interestingly, AR mRNA 
and protein expression in CWR-R1 cells did not respond to EPI-001, nor did EPI-
001 inhibit the expression of the AR target gene FKBP5 (Figure 2.9B). 
To test if the effects of EPI-001 on AR expression were due to decreased AR 
mRNA stability, we treated LNCaP with Actinomycin D alone or in combination 
with EPI-001. Treatment with EPI-001 did not accelerate AR mRNA decay  
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 Figure 2.7: LNCaP (left) and C4-2 (Right) were serum starved overnight, then 
treated with 50 μM EPI-001 and/or 10 μM MG-132 as indicated. EPI-001-
mediated AR protein loss occurred between 8 and 16 hours and was not 
reversed by proteasome inhibitor treatment. 
 
 
 
Figure 2.8: AR mRNA expression was analyzed by qRT-PCR at indicated time-
points in LNCaP (left) and C4-2 (right) cells treated with 50 μM EPI-001. n = 3 
from a triplicate experiment representative of two biological replicates. * = P < 
0.05; ** = P < 0.01; *** = P < 0.001. 
 
 
following transcriptional blockade with Actinomycin D (Figure 2.10). Consistent 
with this, we found that 50 μM EPI-001 reduced the rate of nascent AR mRNA 
synthesis in LNCaP cells (Figure 2.11). Collectively, these data demonstrate that 
EPI-001 inhibits transcription of the AR gene. 
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Figure 2.9 LAPC4 (A) and CWR-R1 (B) cells were cultured in androgen-depleted 
medium for 48 hours, then treated 24 hours in serum-free medium with 
Mibolerone and/or EPI-001 or vehicle control as indicated. RNA extracts were 
prepared and subjected to qRT-PCR for total AR (left panels) and AR targets 
(right panels). 
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 Figure 2.10: LNCaP cells were serum-starved overnight, then treated with 10 
μg/mL Actinomycin D +/- 50 μM EPI-001 for the indicated times. qRT-PCR 
analysis of AR mRNA expression relative to GAPDH was performed. Treatment 
with EPI-001 did not affect the rate of mRNA decay relative to Actinomycin D 
alone. Bars represent mean +/- SD of a triplicate experiment (n = 3), which was 
validated in a repeat triplicate experiment.  
 
 
Figure 2.11: LNCaP cells were treated with 50 μM EPI-001 or vehicle control for 
8 h in serum free medium. Nascent transcripts were isolated and subjected to 
qRT-PCR using primers for AR pre-mRNA (Exon 1 FW & Intron 1 RV) or spliced 
mRNA (Exon 1 FW & Exon 2 RV). Bars depict mean +/- standard deviation of n = 
6 from two biological replicates performed in triplicate).  ** = P < 0.01; **** = P < 
0.0001. 
 
 
Inhibition of AR expression correlates with reduced cell growth in PCa and CRPC 
cell lines. 
 Based on these findings, we reasoned that inhibition of AR synthesis could 
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be an important component of the EPI-001 anti-AR mechanism. EPI-001 
inhibited growth of LNCaP cells at low concentrations, but in all other PCa cell 
lines, the concentrations at which EPI-001 inhibited growth (Figure 2.12A) were 
the same concentrations that inhibited expression of AR or AR-V protein levels 
(Figure 2.12B). BABDHE also inhibited PCa and CRPC growth and AR 
expression, although higher doses were required than for EPI-001 (Figure 2.13),  
 
 
Figure 2.12: (A) LNCaP, C4-2, and 22Rv1 cells were treated for 7 days in 
steroid-depleted medium containing 1 nM DHT and/or EPI-001 as indicated. 
Growth was monitored by crystal violet staining. Bars depict mean +/- standard 
deviation (n = 3 from a triplicate experiment representative of two biological 
replicates). (B) LNCaP, C4-2, and 22Rv1 cells were treated for 24 hours in serum 
free medium as in (A) and subjected to western blot. Densitometry data are 
provided. Bars depict mean +/- standard deviation (n = 3 from a triplicate 
experiment representative of two biological replicates). * = P < 0.05; ** = P < 
0.01, *** = P < 0.001, **** = P < 0.0001. 
 
indicating the EPI-001 chlorohydrin moiety is important for inhibition of AR 
expression. Surprisingly, EPI-001 also inhibited growth of AR-negative PC-3 and 
DU 145 cell lines (Figure 2.14), as well as the T47D breast carcinoma cell line 
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(Figure 2.15A and B). In T47D, reduced expression of AR as well as estrogen 
and progesterone receptors (ER and PR) was observed (Figure 2.15C). These 
data signify AR-independent effects of EPI-001 in multiple cell types.  
 
Figure 2.13: LNCaP, C4-2, and 22Rv1 cells were seeded as in Figure 2.12 and 
treated with 1 nM dihydrotestosterone +/- BABDHE at indicated concentrations, 
then subjected to crystal violet growth assays (A) or western blots (B). Bars 
represent mean +/- SD for a triplicate experiment (n = 3), which was validated in 
a repeat triplicate experiment. * = P < 0.05; ** = P < 0.01, **** = P < 0.0001.  
 
 
Figure 2.14: AR-negative PC-3 and DU 145 cells were treated with EPI-001 and 
analyzed for growth exactly as in Figure 2.12A. Bars depict mean +/- standard 
deviation (n = 3 from a triplicate experiment representative of two biological 
replicates). * = P < 0.05; ** = P < 0.01, *** = P < 0.001 
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 Figure 2.15: (A) T47D cells were seeded in MEM +5% FBS and treated with 
EPI-001 or enzalutamide as indicated for 7 days, then stained with crystal violet. 
(B) Cells were seeded as in (A) and treated with increasing doses of EPI-001 for 
7 days, then stained with crystal violet. (C) Western blot of T47D lysates treated 
overnight with EPI-001 in serum-free MEM as indicated. Denitometry 
measurements are included below their corresponding bands. Bars represent 
mean +/- SD from a triplicate experiment (n = 3), which was validated in an 
independent triplicate experiment. ** = P < 0.01, *** = P < 0.001. 
 
EPI-001 action in PCa cells is similar to the PPARγ agonist, troglitazone. 
 Bisphenol A Diglycidyl Ether (BADGE), which is related structurally to EPI-
001 but contains a bis-epoxide, has been shown to act as a selective PPARγ 
modulator (SPPARM) with diverse effects in different cell types [96-98]. Given 
that PPARγ has also been shown to play a role in prostate development and 
maintenance [99], and PPARγ agonists such as troglitazone have been 
demonstrated to inhibit AR expression and PCa cell growth in vitro and in vivo  
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 Figure 2.16: (A) LNCaP cells were transfected with sPSA-Luciferase, treated 
with troglitazone (TGZ) or EPI-001 as indicated, and subjected to luciferase 
assay. (B) LNCaP cells were treated with troglitazone (TGZ) or EPI-001 as 
indicated and subjected to western blot. (C) LNCaP and 293T were transfected 
with the indicated Gal4-tethered AR constructs and either sPSAGal4-Luciferase or 
pG5-Luciferase, respectively, and treated with 10 μM troglitazone or vehicle 
control as indicated. Bars represent mean +/- standard error (n=6 samples from 
two independent triplicate experiments). * = P < 0.05; ** = P < 0.01, *** = P < 
0.001. 
 
[100-102], we reasoned that PPARγ modulation may be an unanticipated activity 
of EPI-001 in PCa cells. Indeed, troglitazone or EPI-001 caused inhibition of AR 
transcriptional activity in promoter reporter assays in LNCaP cells (Figure 2.16A) 
at doses that correlated with inhibition of AR protein expression (Figure 2.16B). 
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Furthermore, treatment of LNCaP cells with troglitazone or EPI-001 resulted in 
dose-dependent reduction of AR protein levels as well as induction of p21 and 
p27 (Figure 2.16B). Troglitazone inhibited AR expression at lower doses than 
observed in prior studies [101,103], which may be due to the absence of serum 
in the cell culture medium during drug treatment in our study. Finally, troglitazone 
treatment also inhibited the activity of ARGal4, as well as the Gal4-tethered AR 
NTD, TAU1, and TAU5 (Figure 2.16C), analogous to the effect of EPI-001 in 
these models (Figures 2.3 and 2.5).  
 To expand these observations to clinical disease, we treated fresh human 
PCa tissue maintained as explants [104-106] with troglitazone and EPI-001 
(Figure 2.17A). The doses of EPI-001 and troglitazone used in this model were 
increased 2- to 4-fold relative to in vitro experiments to reflect the higher doses of 
drug that have been used for in vivo [78] or ex vivo [107] experimentation. 
Importantly, both EPI-001 and troglitazone effected decreases in AR protein, AR 
mRNA, and AR target gene expression in PCa explants (Figure 2.17B and C). 
 
EPI-001 is a selective modulator of PPARγ in PCa cells. 
We next tested for SPPARM activity of EPI-001 in PCa cells.  Similar to 
troglitazone, EPI-001 activated a PPARγ-response element (PPRE)-regulated 
luciferase reporter in LNCaP cells (Figure 2.18A). This SPPARM activity was AR-
independent, as troglitazone and EPI-001 both induced mRNA expression of the 
PPARγ targets CIDEC [108], TXNIP [103], and PDK4 [99] in the AR-null PC-3 cell 
line [100] (Figure 2.18B). However, in 3T3-L1 cells that had been differentiated to 
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 Figure 2.17: (A) Schematic of explant model for culturing fresh prostate cancer 
tissue. (B and C) PCa tissue explants were treated with EPI-001 or troglitazone 
(TGZ) as indicated for 48 h, then subjected to (B) western blot or (C) qRT-PCR. 
Box plots represent mean and range of two replicates from three patients each 
per treatment condition (n = 6). * = P < 0.05; ** = P < 0.01, *** = P < 0.001, **** = 
P < 0.0001. 
 
 
 
Figure 2.18: (A) LNCaP cells were transfected with PPREx3-TK-Luciferase, 
treated as indicated for 8 h, and subjected to luciferase assay. (B) PC-3 cells 
were treated with EPI-001 overnight and RNA was isolated for analysis of PPARγ 
target gene expression by qRT-PCR. Bars represent mean +/- standard error 
(n=6 from two independent triplicate experiments). * = P < 0.05; ** = P < 0.01, *** 
= P < 0.001, **** = P < 0.0001. 
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PPARγ-positive adipocytes, EPI-001 repressed expression of classical PPARγ 
target genes aP2 and LPL (Figure 2.19A) and inhibited lipid droplet formation 
(Figure 2.19B). These effects are consistent with previous reports of BADGE- 
mediated repression of PPARγ activity in 3T3-L1 adipocytes at micromolar 
concentrations [96]. Taken together, these cell type-specific PPARγ 
agonist/antagonist effects support a SPPARM function for EPI-001, with  
 
 
Figure 2.19: 3T3-L1 fibroblasts were grown to confluence and differentiated into 
mature adipocytes in the presence of rosiglitazone or EPI-001 as indicated. Cells 
were then lysed and subjected to qRT-PCR for PPARγ target genes (A) or 
stained with Oil Red O to measure lipid droplet accumulation (B). Bars represent 
mean +/- SE of n = 6 samples from two independent biological replicates. * = P < 
0.05; ** = P < 0.01, **** = P < 0.0001 relative to untreated control. 
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Figure 2.20: (A) LNCaP cells were transfected with 300 pmol siRNA against AR, 
PPARγ, or nontargeting control and cultured in RPMI +10% CSS for 48 hours, 
then treated as indicated overnight in serum-free RPMI prior to lysis for western 
blot for AR, PPARγ, and β-Actin (loading control). (B) LNCaP were seeded in 
RPMI +10%CSS, then treated overnight as indicated prior to lysis for western 
blot for Sp1 or β-Actin (loading control). V = vehicle, T = 10 μM troglitazone, E = 
50 μM EPI-001. 
 
thiazolidinedione-like effects on PPARγ activity in PCa cells.  
 To investigate the relationship between EPI-001-mediated PPARγ 
activation and AR inhibition, we knocked down PPARγ with siRNA in LNCaP 
cells. Despite effective silencing of PPARγ expression, both troglitazone and EPI-
001 maintained robust inhibition of AR protein expression (Figure 2.20A). This 
finding is consistent with a previous study showing that troglitazone-mediated 
inhibition of AR expression is due to PPARγ-independent degradation of the 
42 
transcription factor Sp1 [101].  However, EPI-001 had no effect on Sp1 levels 
(Figure 2.20B). Conversely, siRNA-mediated knock down of PPARγ partially 
rescued the inhibition of AR transcriptional activity effected by EPI-001, but not 
troglitazone (Figure 2.21), demonstrating that PPARγ participates in EPI-001-
mediated inhibition of AR transcriptional activity, but not inhibition of AR 
expression.  
 
 
Figure 2.21: LNCaP cells were transfected with siRNAs targeting AR or PPARγ 
and treated with mibolerone (Mib), troglitazone (TGZ) or EPI-001 as indicated.  
Expression of AR target genes PSA (A) and hK2 (B) was analyzed by qRT-PCR. 
Bars represent mean +/- standard deviation (n = 2 from a duplicate experiment 
representative of 3 biological replicates). 
 
 
EPI-001 forms covalent adducts with thiols in vitro. 
Because SPPARM activity did not fully account for the multi-level anti-AR effects 
of EPI-001, we considered the fact that Bisphenol A (BPA) and BADGE are 
endocrine disruptors used in the production of polycarbonate plastics and epoxy 
resins [109,110]. The epoxide rings in BADGE and related compounds readily  
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 Figure 2.22: (A) Reaction scheme for conversion of EPI-001 to compound 2. 
EPI-001 was shaken at 37 oC in PBS/DMSO at pH 2.4, 7.4, and 9.4. (B) HPLC 
chromatograms for conversion of EPI-001 to compound. Reaction mixtures were 
analyzed by LC-MS to confirm the presence of epoxide; m/z [M+H]+ 359.2 
(calc’d); 359.0 (found). New peaks that arose during the course of the reaction 
and are distinct from background signals (Supplementary Fig. 20A) are denoted 
with an asterisk. Percent remaining was calculated by dividing the amount of 
measured EPI-001 remaining at t = 12 h by the amount remaining at t ~ 30 min 
and multiplying by 100%. Experiments were performed in triplicate and values 
shown are mean +/- standard deviation. EPI-001:thiol adducts were 
characterized by LC-MS. 
 
undergo hydrolysis and hydrochlorination reactions with substrates in aqueous 
solution [111], resulting in hydroxylated and halogenated derivatives, of which 
EPI-001 (BADGE.HCl.H2O) is one example [112]. Chlorohydrin moieties also 
have the potential to spontaneously interconvert to epoxides in aqueous solution 
[113]. Therefore, we used HPLC to interrogate whether EPI-001 can convert to a 
BADGE-like mono-epoxide in solution (Compound 2, Figure 2.22A). Indeed, the 
epoxide was observed after 12h incubation at neutral and basic pH (Figure 
2.22B), but not under acidic conditions (Figure 2.23). The identity of compound 2 
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 Figure 2.23: (A) Spontaneous conversion of the EPI-001 chlorohydrin to a 
reactive epoxide. EPI-001 was shaken at 37 oC in aq. PBS / DMSO (~10:1) at pH 
2.4. The reactions were analysed by reverse-phase HPLC at t ~30 min and t = 12 
h for the appearance of epoxide. (B) The reaction mixtures were analyzed by LC-
MS confirming the absence of epoxide. 
 
was confirmed by co-injection with an authentic standard and LC-MS analysis 
(Figure 2.24). BADGE has been shown to react with nucleophilic side chains of  
food proteins in plastic-lined cans [114], which is the same reaction proposed for 
the specific AR-binding mechanism of EPI-001 [78]. In a previous study, non-
specific reactivity of EPI-001 with nucleophilic thiols was not observed [78]. 
However, given our observation that EPI-001 spontaneously converts to the 
epoxide at neutral and basic pH, and that BADGE is reactive to nucleophiles, we 
queried reactivity of EPI-001 with the nucleophilic thiols glutathione, 2-
mercaptoethanol, and cysteamine at various pH conditions (Figure 2.25A). 
Reaction of EPI-001 with glutathione resulted in a trace amount of thiol adduct  
 
45 
  
Figure 2.24: A solution of EPI-001 in aq. PBS / DMSO incubated 12 h at pH = 
9.4 was spiked with 12 uL of 8.5 mM Compound 2 in DMSO. The EPI-001 
degradation product and the co-injected standard eluted from the column in 
tandem (marked with an asterisk). 
 
formation at pH 7.4, and nearly complete conversion to the glutathione adduct at 
pH 9.4 after 12 hours (Figure 2.25B). No EPI-001:thiol adducts were formed  
under acidic conditions (Figures 2.26 and 2.27). Similarly, 2-mercaptoethanol 
displayed limited adduct formation at neutral pH, but underwent complete 
conversion to the EPI-001:thiol adduct at basic pH (Figure 2.25B). Finally, EPI-
001 did not react with cysteamine at pH 7.4, but displayed nearly complete 
adduct formation at pH 9.4 (Figure 2.25B). All EPI-001-thiol adducts were 
confirmed by mass spectrometry (Figure 2.28). Additionally, the monoepoxide, 
compound 2, formed adducts with all thiols examined and displayed an 
enhanced reactivity profile overall (Figure 2.29). Collectively, these data indicate 
that EPI-001 spontaneously converts to the more reactive epoxide in solution at 
neutral and basic pH. Furthermore, EPI-001 extensively alkylates thiols under 
basic conditions with appreciable amounts of EPI-001:thiol adducts observed at 
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neutral (7.4) pH. Our results suggest that EPI-001 is a reactive electrophile which 
may display some selectivity in modulation of proteins by virtue of local pH 
influence. 
 
 
Figure 2.25: (A) Scheme for covalent modification of EPI-001 by reactive thiols. 
Solutions of EPI-001 and thiols in PBS/DMSO at pH 2.4, 7.4, and 9.4, 
respectively, were shaken at 37 oC. (B) HPLC chromatograms for covalent 
adduct formation between EPI-001 and thiols (t = 12 h). New peaks that arose 
during the course of the reaction and are distinct from background signals 
(Supplementary Fig. 20A) are denoted with an asterisk. Percent remaining was 
calculated by dividing the amount of measured EPI-001 remaining at t = 12 h by 
the amount remaining at t ~ 30 min and multiplying by 100%. Experiments were 
performed in triplicate and values shown are mean +/- standard deviation. EPI-
001:thiol adducts were characterized by LC-MS. 
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 Figure 2.26: (A) Solutions of EPI-001 and thiol in aq. PBS / DMSO (~10:1) at pH 2.4, 7.4, and 9.4, respectively, were shaken at 37 oC. The 
reactivity of the following thiols with EPI-001 was investigated: reduced L-glutathione, 2-mercaptoethanol, and cysteamine. The reactions were 
analyzed by reverse-phase HPLC at t ~30 min for the appearance of thiol adducts. (B) At t ~ 30 min, EPI-001 adducts were only observed under 
strongly basic conditions (pH=9.4). Under such conditions, EPI-001 exhibits reactivity with each of the three thiols. New products formed during 
the course EPI-001-thiol incubation are marked with an asterisk. Background signals collected in the absence of EPI-001 are shown in 
Supplementary Figure S20A. Experiments were performed in triplicate, and the identities of the monoadducts were confirmed by LC-MS. 
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 Figure 2.27: (A) Reaction schematic demonstrating covalent modification of 
reactive thiols by EPI-001. Solutions of EPI-001 and thiol in aq. PBS / DMSO 
(~10:1) at pH 2.4 were shaken at 37 oC. The reactivity of the following thiols with 
EPI-001 was investigated: reduced L-glutathione, 2-mercaptoethanol, and 
cysteamine. The reactions were analyzed by reverse-phase HPLC at t = 12 h for 
the appearance of thiol adducts. (B) At t = 12 h, no new peaks were observed 
under acidic conditions. 
 
 
DISCUSSION 
 
In this study, we describe unanticipated multi-level effects of EPI-001 on the AR 
and PPARγ pathways, leading to inhibition of cell growth. In previous reports, 
EPI-001 was shown to bind specifically to the AR NTD through a nucleophilic 
substitution reaction with the EPI-001 chlorohydrin group [78], thereby inhibiting 
AR activity via occlusion of an unidentified CBP binding domain [77]. We were 
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 Figure 2.28: (A) Mass spectrum of the monoadduct of glutathione and EPI-001; 
m/z [M+H+] 666.3 (calc’d); 666.3 (found). (B) Mass spectrum of the monoadduct 
of 2-mercaptoethanol and EPI-001; m/z [M+H+] 437.2 (calc’d); 437.2 (found). (C) 
Mass spectrum of the monoadduct of cysteamine and EPI-001; m/z [M+H+] 436.2 
(calc’d); 436.3 (found) 
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Figure 2.29 (cont’d next page) 
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 (Cont’d) Figure 2.29: (A) Solutions of epoxide and thiol in aq. PBS / DMSO (~10:1) at pH 2.4, 7.4, and 9.4, respectively, were 
shaken at 37 oC. The reactivity of the following thiols with epoxide was investigated: reduced L-glutathione, 2-mercaptoethanol, 
and cysteamine. The reactions were analyzed by reverse-phase HPLC at t ~30 min and t = 12 h for the appearance of thiol 
adducts. (B) At t ~ 30 min, a GSH/epoxide monoadduct was observed under basic conditions (pH = 9.4) as the primary 
component of the reaction mixture. At pH = 7.4, a 2-mercaptoethanol monoadduct was observed. At pH = 9.4, no evidence of the 
epoxide remained and only the monoadduct was present. (C) At t = 12 h, a multitude of new peaks (many are thiol adducts) were 
observed following incubation of Compound 2 with each thiol. New products formed during the course Compound 2-thiol 
incubation are marked with an asterisk. Background signals collected in the absence of Compound 2 are shown in Supplementary 
Figure S20A. Experiments were performed in triplicate, and the identities of the explicitly assigned monoadducts were confirmed 
by LC-MS. 
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unable to nominate a discrete AR NTD motif that could account for a specific 
mechanism of EPI-001-mediated AR transcriptional repression in this study. 
Conversely, we found that EPI-001 inhibited synthesis of AR in PCa cell lines and 
clinical tissues at doses that corresponded with the inhibition of AR target genes 
and PCa cell growth. The LNCaP cell line was an exception to this general dose 
relationship between AR expression inhibition and cell growth inhibition, 
displaying the highest sensitivity to EPI-001- and BABDHE-mediated growth 
inhibition. This is important, as the majority of pre-clinical data supporting the 
efficacy and specificity of EPI-001 for AR has been generated using the LNCaP 
model [77,78]. Moreover, we found that EPI-001 inhibited the growth of AR-
negative PC-3 and DU 145 cells. These data conflict with a previous report [77], 
but we propose that this discrepancy is due to two key differences in 
experimental design. First, our study incorporated longer-term (i.e. 7 day) growth 
assays as opposed to early time point (i.e. 3 day) BrdU incorporation readouts. 
Secondly, previous reports used 10 μM EPI-001 to treat PC-3 and DU 145, a 
dose which was not inhibitory to the growth of PC-3 and DU 145 in our study, but 
inhibitory LNCaP cells. These data highlight the cell line-specific responses to 
EPI-001, which supported earlier conclusions of AR specificity. 
Our data indicate that PPARγ activation represents at least one AR-
independent activity of EPI-001 in PCa cells. However, EPI-001 displayed PPARγ 
inhibitory activity in a classical 3T3-L1 adipocyte differentiation model, indicating 
SPPARM activity as opposed to pure agonist activity. SPPARM activity for EPI-
001 is consistent with studies demonstrating that the structurally-related 
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compound, BADGE, is a SPPARM that binds to the PPARγ LBD [96] and exhibits 
distinct molecular effects in PCa and 3T3-L1 cells when compared with synthetic 
thiazolidinedione PPARγ agonists [96-98] including troglitazone [109-111]. 
Furthermore, our data from thiol reactivity assays demonstrate that small 
molecule thiolates (e.g., glutathione, 2-mercaptoethanol, cysteamine) are readily 
alkylated by EPI-001 and this reactivity is attenuated at acid and neutral pH 
conditions. Consequently, our data suggest that any protein bearing an 
accessible nucleophilic residue within a suitably basic binding pocket may be a 
target for covalent modification by EPI-001. This is further supported by the 
established reactivity of BADGE in vitro [114], and our data that EPI-001 is 
converted to an analogous epoxide (compound 2) in solution at physiological pH. 
Collectively, these data suggest EPI-001 and BADGE bear substantial proteome 
reactivity features in addition to their reported interactions with AR and PPARγ.  
These new data indicate that structural changes to the core bisphenol of EPI-001 
as well as the covalent warhead may be required to mitigate the AR-independent 
effects reported in this study and in the toxicology literature [109-111,114,115]. 
However, this task is complicated because no 3-dimensional structure has been 
reported for the intrinsically disordered AR NTD [116,117], which impedes the 
rational design of improved inhibitors.  Nevertheless, EPI-002, the (2R, 20S) 
isomer of racemic EPI-001, has been shown to display stronger AR interactions 
and reduced toxicity in mice [78], indicating this direction may be feasible. Our 
findings that EPI-001-mediated inhibition of AR activity is associated with 
inhibition of AR expression and activation of PPARγ in PCa, coupled with the 
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finding that EPI-001 can capture nucleophilic thiols, will be important for ongoing 
pre-clinical development of EPI-001 and other anti-AR compounds that target 
functional domains independent of the AR LBD. 
 
MATERIALS AND METHODS 
 
Cell Culture and Growth Assays 
 LNCaP, C4-2, DU 145, VCaP, 22Rv1, 293T, and PC-3 cell lines were obtained 
from ATCC. The ATCC validates the authenticity of these cell lines via short 
tandem repeat (STR) analysis.  CWR-R1 prostate cancer cells were the 
generous gift of Dr. Elizabeth Wilson (University of North Carolina at Chapel Hill, 
Chapel Hill, NC). CWR-R1 cells were authenticated by sequence-based 
validation of two characteristic AR mutations: a H874Y mutation in the LBD, and 
a 50 kb deletion in AR intron 1 [67]. VCaP and 293T were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% FBS. All other cell lines 
were maintained in RPMI 1640 medium with 10% FBS, and all cell lines were 
maintained in 100 Units/mL Penicillin + 0.1 mg/mL Streptomycin. Cells were 
cultured in a 37o C incubator with 5% CO2 for no longer than 15 passages after 
resuscitation of frozen stocks. Cell growth was assessed by crystal violet staining 
as previously described [65]. T47D breast cancer cells were the generous gift of 
Dr. Carol Lange (University of Minnesota, Minneapolis, MN). Cells were 
maintained in Minimal Essential Medium (MEM) supplemented with 5% Fetal 
Bovine Serum (FBS), 5 mg/mL insulin, 2 mM L-glutamine, 100 Units/mL 
55 
Penicillin, and 0.1 mg/mL Streptomycin. 3T3-L1 cells (kindly provided by Dr. 
David Bernlohr from the Department of Biochemistry, Molecular Biology and 
Biophysics, University of Minnesota) were cultured in DMEM with 10% bovine 
calf serum (Sigma Aldrich, Saint Louis, MO) and 100 IU/ml penicillin/streptomycin 
(Invitrogen, Carlsbad, CA) until confluence. Two days after confluence, cells were 
subjected to two-day incubation in the adipocyte differentiation cocktail containing 
10% fetal bovine serum (JRH Biosciences, Inc., Lenexa, KS), 115 mg/ml 
methylisobutylxanthine (Sigma Aldrich, Saint Louis, MO), 1mg/ml insulin (Sigma 
Aldrich, Saint Louis, MO), and 390 ng/ml dexamethasone (Sigma Aldrich, Saint 
Louis, MO). During the following 6 days, cells were maintained in DMEM 
containing 10% fetal bovine serum, 100 IU/ml penicillin/streptomycin and 1mg/ml 
insulin until fully differentiated with robust accumulation of lipid droplets. In the 
treated groups, Rosiglitazone at the concentration of 1 μM or EPI at various 
concentrations was added to the cultures during the entire 8-day differentiation 
period. On day 8, cells were stained with Oil-red O or harvested for RNA 
extraction. 
 
Reagents 
Dihydrotestosterone (DHT), mibolerone (MIB), and BABDHE (Bisphenol A 
bis[2,3-dihydroxypropyl] ether) were purchased from Sigma. Enzalutamide (ENZ) 
was purchased from Selleck Chemicals. Troglitazone was purchased from 
Cayman Chemical. EPI-001 (Bisphenol A [3-chloro-2-hydroxypropyl][2,3-
dihydroxypropyl] ether) was synthesized (See Appendix) or purchased from 
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commercial sources (Santa Cruz Biotechnology or Sigma-Aldrich). EPI-001 was 
analyzed for purity via HPLC and NMR (Appendix, Figures A1 and A2). EPI-001 
was dissolved in DMSO was used for all experiments (Appendix, Figure A3). All 
other drugs were suspended in DMSO with the exception of DHT, MIB, and ENZ, 
which were prepared in absolute ethanol. Final DMSO or ethanol concentrations 
did not exceed 0.1% (v/v) in culture medium. 
 
Table 2.1: Mutagenic Primer Sequences 
Amplicon Direction Cut site Sequence (5'  3') 
TAU1 F EcoR1 CGGAATTCCGTAGAGGCCCCACAGGCTACC 
TAU1 R  BamH1 CGGGATCCTCACTGGTACGCAGCTGCCTCGTCC 
TAU5 F EcoR1 CGGAATTCAGTCGCGACTACTACAACTTTCCACT 
TAU5 R  BamH1 CGGGATCCTCACAGCCCCTGAGGGGGCCGAGT 
 
 
Plasmids  
Plasmids encoding human AR (p5HBhAR-A), ARGal4, NTD-Gal4, ARGal4∆TAU1, 
ARGal4∆TAU5, sPSA-Luciferase (also referred to as PSAenh(ARE)-LUC), and 
sPSAGal4-Luciferase (also referred to as PSAenh(GAL4)-LUC) have been 
described [73]. SV40-Renilla, CMV-Renilla, and pG5-Luciferase were purchased 
from Promega. PPREx3-TK-Luciferase has been described [118], and was 
obtained from Addgene. The Gal4 DBD expression plasmid (pM) was purchased 
from Clontech. Gal4 tethering of AR TAU1 (amino acids 101-360) and TAU5 
(amino acids 361-490) was achieved by PCR amplification of TAU1 or TAU5 from 
p5HBhAR-A using primers listed in Table 2.1. Primers were designed to introduce 
in-frame recognition sites for EcoRI and BamHI, which were used to ligate the 
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insert with EcoRI/BamHI-digested pM.  
 
Western Blot 
Western blotting with antibodies listed in Table 2.1 was performed as previously 
described [65].  
 
 Table 2.2: Primary and Secondary Antibodies 
Target Epitope Type Vendor Catalog # 
AR 
 
N-20 Rabbit Polyclonal Santa Cruz sc-816 
ERK2 
 
D-2 Mouse Monoclonal Santa Cruz sc-1647 
Gal4 
 
DBD Rabbit Polyclonal Santa Cruz sc-577 
Lamin A/C 
 
4C11 Mouse Monoclonal Cell Signaling 4777 
PPAR-gamma 
 
81B8 Rabbit Monoclonal Cell Signaling 2443 
beta-Actin 
 
AC-15 Mouse Monoclonal Sigma A1978 
HRP-Conjugated 
Secondary Ab 
 
Mouse IgG Goat Santa Cruz sc-2005 
HRP-Conjugated 
Secondary Ab 
 
Rabbit IgG Goat Santa Cruz sc-2004 
 
Cell Transfection 
LNCaP cells were transfected via single-pulse electroporation as previously 
described [45]. C4-2 cells were transfected with Superfect reagent (Qiagen) 
according to manufacturer specifications. 293T cells were transfected with 
Lipofectamine 2000 (Life Technologies) according to manufacturer specifications. 
Treatment of transfected cells with androgen and/or drug was performed for 8 
hours or overnight in serum-free medium as indicated.  
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 Dual Luciferase Assays 
Transfected cells were lysed in 1X Passive Lysis Buffer (Promega) and subjected 
to dual luciferase assays using a Dual Luciferase Assay Kit (Promega) as 
previously described [45]. 
 
Proteasome Inhibition 
LNCaP and C4-2 were seeded in RPMI +10% CSS. Cells were then serum-
starved overnight and co-treated with 10 μM MG-132 (Sigma) and/or 50 μM EPI-
001 and harvested at the indicated time points for western blot. 
 
Nascent RNA Labeling and Isolation 
Nascent transcripts were labeled with biotin and subjected to streptavidin pull-
down using the Click-iT Nascent RNA Capture Kit (Life Technologies) according 
to manufacturer specifications. Briefly, LNCaP cells were serum-starved 
overnight, then treated with 50 μM EPI-001 or vehicle control. After 7 hours 
incubation, cells were pulsed with 5-ethynyl Uridine (5EU) for an additional hour 
in the presence of EPI-001 or vehicle to label nascent transcripts, then harvested 
in Trizol (Life Technologies). Total RNA was then subjected to a Click chemistry 
reaction which attached a biotin molecule to 5EU-labeled nascent transcripts. 
RNA was re-precipitated, then bound to streptavidin-conjugated magnetic beads 
and washed 10X to remove unlabeled transcripts, leaving only biotin-5EU-
labeled nascent RNA attached to the beads. First-strand cDNA synthesis was 
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performed directly on RNA:bead conjugates using the SuperScript VILO cDNA 
synthesis kit (Life Technologies) according to manufacturer specifications, then 
subjected to qRT-PCR. 
 
Quantitative RT-PCR  
RNA isolation and quantitative RT-PCR analysis were performed as described 
[[65]] using primers listed in Supplementary Table 3. 
 
 Table 2.3: qPCR Primer Sequences 
Gene Species Direction Sequence (5'  3') 
AR Exon1 Human F TGG ATG GAT AGC TAC TCC GG 
AR Intron 1 Human R TTT ACC CTG CTG AGC TCT CC 
AR Exon2 Human R CCC AGA AGC TTC ATC TCC AC 
PSA Human F AGG CCT TCC CTG TAC ACC AA 
PSA Human R GTC TTG GCC TGG TCA TTT CC 
hK2 Human F CTG TCA GAG CCT GCC AAG AT 
hK2 Human R GCA AGA ACT CCT CTG GTT CG 
TMPRSS2 Human F CTG CCA AGG TGC TTC TCA TT 
TMPRSS2 Human R CTG TCA CCC TGG CAA GAA TC 
FKBP5 Human F AGG AGG GAA GAG TCC CAG TG 
FKBP5 Human R TGG GAA GCT ACT GGT TTT GC 
CIDEC Human F ATT GAT GTG GCC CGT GTA ACG 
CIDEC Human R CAG CAG TGC AGA TCA TAG GAA A 
PDK4 Human F AGA GGT GGA GCA TTT CTC GC 
PDK4 Human R ATG TTG GCG AGT CTC ACA GG 
Actin Human F ATG CAG AAA GAG ATC ACC GC 
Actin Human R ACA TCTGCT GGA AGG TGG AC 
GAPDH Human F GAA GGT GAA GGT CGG AGT C 
GAPDH Human R GAG GAT GGT GAT GGG ATT TC 
TBP Mouse F GAA GAA CAA TCC AGA CTA GCA GCA 
TBP Mouse R CCT TAT AGG GAA CTT CAC ATC ACA G 
aP2 (FABP4) Mouse F GAT GAA ATC ACC GCA GAC GAC A 
aP2 (FABP4) Mouse R ATT GTG GTC GAC TTT CCA TCC C 
LPL Mouse F TGA GAA AGG GCT CTG CCT GA 
LPL Mouse R GGG CAT CTG AGA GCG AGT CTT 
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Prostate Cancer Explants 
Patient tissues were obtained from the University of Texas Southwestern Medical 
Center tissue core under UTSW IRB STU 112013-056 and explant studies were 
performed as previously described [104,105]. Briefly, cancerous prostates were 
excised from patients with high-risk (GG8-10) high volume (>2 positive cores) 
prostate cancers via robotic laparoscopic prostatectomy.  Pathology-validated 
cancer tissue was dissected into 1 mm3 cubes, and cultured on Surgifoam oral 
gelatin sponges (Ethicon) for 24 hours in RPMI + 10% FBS supplemented with 
insulin and hydrocortisone at 10 mg/L each. Explants were then washed 3 x 1 hr 
in RPMI + 10% CSS supplemented +/- 1 nM Mibolerone alone or in combination 
with Troglitazone (10 or 50 μM) or EPI-001 (50, 100, or 200 μM) as indicated. 
Tissue explants were then cultured in RPMI + 10% CSS supplemented with 1 nM 
Mibolerone alone or in combination with Troglitazone or EPI-001 for 48 hrs at 37o 
C. Explants were then removed from the sponges and lysed for western blot or 
qRT-PCR analysis using a tissue grinder in the appropriate lysis buffer. 
 
Oil Red O Staining 
Oil-red O staining was performed on 3T3-L1 cell cultures as previously described 
[119]. Briefly, cells were fixed in Baker’s Formalin for 30 min at room temperature, 
followed by staining in a 60% (w/v) solution of Oil-red O (Sigma-Aldrich, 
Milwaukee, WI) in isopropyl alcohol for 10 min. 
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pH Stability Studies of EPI-001 and Thiol Reactivity Assays  
2-Mercaptoethanol, cysteamine, and rose bengal were purchased from Sigma-
Aldrich, and reduced glutathione and tris(2-carboxyethyl)phosphine hydrochloride 
salt (TCEP•HCl) were purchased from Alfa Aesar. All chemicals were used 
without additional purification unless noted. A solution of thiol (10 equiv.) and 
TCEP•HCl (100 µL of a 0.5 M DMSO stock soln.) in 1x aqueous PBS (5 mL) was 
adjusted to the desired pH (2.4, 7.4, or 9.4) using either aqueous HCl (6 M) or 
aqueous NaOH (6 M) as determined by a pH meter (Thermo Scientific Orion 3 
Star). Reduced l-glutathione, 2-mercaptoethanol, and cysteamine [120], were 
used as thiols in this assay. To a solution of the appropriate individual thiol (170 
µL) was added either EPI-001 or compound 2 (1 equiv.; both compounds were 
solubilized as 50 mM DMSO stock solutions). The total composition of DMSO did 
not exceed 7.5% in any experiment and the ratio of thiol to EPI-001/compound 2 
was 10:1. Note: This order of addition is key to achieving the appropriate pH 
environment for the reaction as the addition of reduced l-glutathione and TCEP 
acidify neutral solutions and cysteamine basifies neutral solutions. Aliquots of 
reactions were analyzed immediately (t ~30 min) following initial mixing by 
reverse phase HPLC and LC-MS. Reactions were gently shaken at 37 oC for 12 
h, then analyzed again using HPLC and LC-MS. Reactions were conducted in 2 
mL clear screw cap glass vials (Agilent Technologies). Note: Thirty minutes was 
the earliest time point that could be collected after adding EPI-001, mixing, and 
injecting an aliquot onto the HPLC. The HPLC analytical method (Zorbax SB-C18 
4.6 x 150 mm, 3.5 µm column, Agilent Technologies; flow rate = 1.0 mL/min) 
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involved isocratic 10% CH3CN in 0.1% (v/v) aqueous CF3CO2H (0 to 2 min), 
followed by linear gradients of 10-85% CH3CN (2-24 min) and 85%-95% CH3CN 
(24-26 min). LC-MS analyses were performed on an Agilent 1100 series 
instrument equipped with an Agilent MSD SL Ion Trap mass spectrometer 
(positive-ion mode) and a Zorbax SB-C18 column (0.5 x 150 mm, 5 µm, Agilent 
Technologies). The analysis method (15 µL/min flow rate) involved isocratic 10% 
MeCN (containing 0.1% TFA) in ddH2O (containing 0.1% HCO2H; 0 to 2 mins) 
followed by a linear gradient of 10% to 90% MeCN (containing 0.1% TFA) in 
ddH2O (containing 0.1% HCO2H; 2 to 24 mins), and isocratic 90% MeCN 
(containing 0.1% TFA) in ddH2O (containing 0.1% HCO2H; 24-26 mins). The 
column was heated to 40 oC. Wavelength monitored = 254 nm for all experiments 
unless otherwise noted. LC-MS analysis was performed on crude reaction 
mixtures. To quantify the amount of parent compound remaining, the area under 
the curve (AUC) of the parent compound was divided by the AUC of an internal 
standard. Rose bengal (7.5 µM) was used as the internal standard and was 
added immediately before HPLC analysis Experiments were performed in 
triplicate and values shown are the mean ± standard deviation (calculated in 
Microsoft Excel). Calibration curves to normalize for injection variances during 
HPLC analysis were generated for each compound (Figure 2.30). For both 
compounds, R2 > 0.99. 
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Data Analysis and Statistics 
All statistical comparisons were made using the two-tailed Student’s t-Test with a 
P value of 0.05 or less considered significant. 
 
 
Figure 3.30: (A) Solutions of the three thiols (glutathione, 2-mercaptoethanol, 
cysteamine) in aq. PBS / DMSO (~10:1) at pH 2.4, 7.4, and 9.4, respectively, 
were shaken at 37 oC. The reactions were analyzed by reverse-phase HPLC at t 
= 12 h to establish background traces. (B) A calibration curve was generated to 
normalize for injection variances during HPLC analysis. 
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CHAPTER 3 
MOLECULAR CHARACTERIZATION OF ANDROGEN RECEPTOR NH2-
TERMINAL TRANSCRIPTIONAL ACTIVATION DOMAINS 
 
 
INTRODUCTION 
 
 The preceding chapters have discussed the impact of prostate cancer 
(PCa) on human health in the US [29], as well as the central role played by the 
androgen receptor (AR) in the development of the prostate and disease 
progression in PCa patients [82]. For patients whose cancer has spread outside 
of the prostate capsule or formed distal metastases, inhibiting AR activity is the 
current standard of care. This is achieved by preventing androgens from binding 
AR, either by blockade of androgen production or competitive inhibition of the 
ligand binding domain (LBD) of the AR [122,123]. While initially effective, these 
strategies ultimately fail through mutation or deletion of the LBD, or amplification 
of the AR gene [124]. These mechanisms render hormone-based therapy 
ineffective and trigger a transition to castration resistant prostate cancer (CRPC), 
for which no cure is currently available [84]. Due to the mutability of the LBD, 
there is an urgent clinical need for AR-targeted therapeutics that bind outside of 
the ligand binding pocket to exert their effect. 
 The AR NH2-terminal domain (NTD) contains the primary transcriptional 
activation functions of the AR (Figure 1.1), and therefore serves as an attractive 
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target for therapeutic intervention. The recent characterization of pathologic AR 
splice variants (ARV) (Figure 1.2) as a major driver of drug resistance in clinical 
specimens highlights the NH2-terminal domain as a target for AR-based PCa 
intervention [125-127]. However, little is known about the functional dynamics of 
the NTD in PCa cells due to a high degree of intrinsic disorder in this domain 
[76,117]. Previous studies have reported a central role for amphipathic helices in 
AR transcriptional activation, namely a 178LKDIL182 motif resident in the AF1a 
region of the TAU1 domain [2,21] and a 435WHTLF439 motif in the TAU5 domain 
[2,71,128] (Figure 1.1). Similar helices have been shown to act as anchors for 
coactivator recruitment and guides for proper folding of intrinsically disordered 
regions (IDR) of cellular proteins [129], but the precise role of LKDIL and WHTLF 
in mediating AR transcriptional activity has been elusive. Additionally, it is 
currently unknown whether the loss of the regulatory LBD influences the relative 
activity of TAU1 and TAU5 in pathologic ARV. Finally, characterization of IDR-
containing proteins has demonstrated that the expression and functional role of 
IDRs can vary significantly between cell types due to factors such as alternative 
splicing, post-translational modification, and differential expression of binding 
partners [129-131]. Much of the initial biochemical characterization of the NTD 
was performed in non-prostate cell lines [19,70,72,75,128,132-134], raising 
concern that data derived from some early models may not accurately reflect the 
role of NTD functional domains in human PCa. Thus, while the AR NTD presents 
an attractive target for PCa intervention, the relevant structural and functional 
elements appropriate for targeting are yet to be clearly defined. 
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 In this study, we performed biochemical assays to assess the functional 
dynamics of the constituent domains of the AR NTD in human prostate cancer 
cells. We showed that the TAU1 LKDIL motif is necessary, but not sufficient, for 
transcriptional activity of the broader TAU1 domain. To this end, we found that an 
additional domain within TAU1, termed AF1b (Figure 1.1), possessed intrinsic 
transactivation activity. Finally, we defined the relative input of TAU1, AF1a, AF1b, 
and TAU5 in AR-V7, an AR splice variant frequently expressed in CRPC. Overall, 
this study provides new insight into the functional dynamics of the AR NTD, and 
provides a framework for future translational studies of this domain. 
 
RESULTS 
 
The LKDIL motif does not recapitulate the full transcriptional activity of TAU1 in 
human AR. 
Given the conclusions of previous studies that identified AR178LKDIL182 as 
the transcriptional core of TAU1 [2], we sought to test whether this mechanistic 
data holds true in the human PCa cells. In order to assess the activity of ectopic 
AR isoforms independently of the endogenous AR, we substituted the AR DNA 
binding domain with the yeast Gal4 DBD. These ARGal4 constructs were then co-
transfected along with the Gal4-responsive sPSAGal4-Luciferase reporter into 
LNCaP and C4-2 PCa cells (Figure 3.1). In androgen sensitive LNCaP cells, 
endogenous ARGal4 activated the sPSAGal4-LUC reporter and this activity was 
further induced upon addition of the synthetic androgen mibolerone (Figure 3.1). 
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ARGal4 also displayed constitutive androgen-independent activity in castration 
resistant C4-2 cells (Figure 3.1). Deletion of AF1a from ARGal4 inhibited 
 
 
Figure 3.1: LNCaP and C4-2 cells were transfected with sPSAGal4-LUC and the 
indicated ARGal4 constructs and treated 24 h with 1 nM Mibolerone or vehicle 
control, then subjected to luciferase assay. Bars represent mean +/- SD of n = 3 
samples representative of two independent experiments. Please see the note in 
Materials and Methods regarding the representation of statistics in this chapter. 
 
transcriptional activity in both cell lines. Restoration of a 21-amino acid peptide 
sequence including the 178LKDIL182 motif (GLSSCSADLKDILSEASTMQL) rescued 
approximately 50% of androgen-induced ARGal4 transcriptional activity in LNCaP 
cells, but did not affect androgen-independent ARGal4 activity in either cell line. 
Given the possibility that a small, 21-amino acid peptide may have omitted 
uncharacterized, LKDIL-proximal regulatory components, we tested whether re-
introduction of larger peptide sequences might enhance transcriptional activity of 
LKDIL within TAU1-deleted ARGal4. Using the +21 peptide as a control, we tested 
three additional fragments of increased length (+25, +29, and +33), as well as a 
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putative “Core TAU1” sequence identified by Calleweart et al. [75] (Table 3.1). 
None of the expanded cassettes enhanced ARGal4 transcriptional activity 
compared with the +21 control (Figure 3.2). Taken together, these data indicate 
an important role for the LKDIL motif in AR-mediated transcriptional activation. 
Furthermore, this work indicates that LKDIL may interact functionally with other 
TAU1 components to support full AR transcriptional activity in human PCa cells. 
 
Table 3.1: Length and sequence of AF1a peptides  
Peptide Size Sequence 
+21 170-GLSSCSADLKDILSEASTMQL-190 
+25 168-FPGLSSCSADLKDILSEASTMQLLQ-192 
+29 166-PTFPGLSSCSADLKDILSEASTMQLLQQQ-194 
+33 164-LGPTFPGLSSCSADLKDILSEASTMQLLQQQQQ-196 
Core TAU1 [134]                    173-SCSADLKDILSEASTMQLLQQQQQ-196 
 
 
AF1b has intrinsic transcriptional activity in human PCa cells and is required for 
full functionality of TAU1 
 We next tested whether small internal deletions within the AF1a 
domain could identify discrete regions that may contribute to LKDIL-mediated 
transcriptional activity in the human AR. A series of six tiling deletions that 
spanned the length of AF1a were prepared in the ARGal4 expression plasmid 
(Figure 3.3). Surprisingly, all AF1a deletions with the exception of ∆125-136  
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 Figure 3.2: LNCaP cells were transfected with sPSAGal4-LUC and the indicated 
ARGal4 constructs and treated overnight with 1 nM Mibolerone or vehicle control, 
then subjected to luciferase assay. Bars represent mean +/- SD for n = 3 samples 
representative of two independent experiments. 
 
 
 
Figure 3.3: LNCaP cells were transfected with sPSAGal4-LUC and the indicated 
ARGal4 constructs and treated overnight with 1 nM Mibolerone or vehicle control, 
then subjected to luciferase assay. Bars represent mean +/- SE for n = 6 samples 
from two independent experiments. 
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reduced androgen-dependent AR activity by approximately 50%, whereas ∆125-
136 had no effect on AR activity (Figure 3.3, black bars). None of the deletions 
appeared to affect androgen-independent AR activity (Figure 3.3, white bars). 
Given that most of the deletions had a similar impact on AR activity in this model, 
we considered whether this approach may be disrupting unknown structural 
elements that could be critical for AR activity in LNCaP, e.g. recruitment of 
transcriptional co-regulators. To assess the transcriptional activity of these same  
 
 
Figure 3.4: LNCaP and 293T cells were transfected with sPSAGal4-LUC or pG5-
LUC, respectively, and the indicated ARGal4 constructs. Superscripted numbers 
denote AR amino acid composition. Cells were incubated overnight in serum-free 
medium, then subjected to luciferase assay. Bars represent mean +/- SE for n = 
6 samples from two biological replicates. 
 
six AF1a sub-regions, we synthesized oligonucleotides coding for each of the 
corresponding regions deleted from AF1b in Figure 3.3 and cloned them into an 
expression vector in-frame with the Gal4 DBD. The resulting Gal4-AF1a fusions 
(Figure 3.4) were then co-expressed in LNCaP or 293T fibroblast cells with a 
Gal4-responsive luciferase reporter. In 293T cells, four of the six constructs 
exhibited intrinsic transcriptional activity (Figure 3.4). However, in LNCaP cells, 
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only the AR152-171 fragment displayed transcriptional activity above the 
background (Figure 3.4). Paradoxically, this construct does not contain the 
178LKDIL182 motif or the Core TAU1 sequence previously shown to harbor intrinsic 
transactivation activities. 
 
 
Figure 3.5: LNCaP and 293T cells were transfected with sPSAGal4-LUC or pG5-
LUC, respectively, and the indicated ARGal4 constructs. Cells were incubated 
overnight in serum-free medium, then subjected to luciferase assay. Bars 
represent mean +/- SE for n = 6 samples from two biological replicates.  
 
 Previous studies of the AR in non-prostate cell lines led to the conclusion 
that the AF1a domain, and the 178LKDIL182 motif in particular, was the primary 
driver of TAU1-mediated AR transcriptional activity [2,70,75]. As demonstrated in 
Figure 3.4 and 3.5, however, ectopically expressed AR fragments may harbor 
different levels of transcriptional activity in prostate vs. non-prostate cells. We 
therefore tested the activity of Gal4-tethered AF1a relative to Gal4-tethered TAU1 
in LNCaP and 293T cells (Figure 3.5). Surprisingly, Gal4-AF1b displayed higher 
transcriptional activity than Gal4-AF1a in both cell lines (Figure 3.5).  
To further characterize the AF1b domain, we introduced tiling deletions  
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 Figure 3.6: LNCaP and 293T cells were transfected with sPSAGal4-LUC or pG5-
LUC, respectively, and the indicated ARGal4 constructs. Cells were incubated 
overnight in serum-free medium, then subjected to luciferase assay. Bars 
represent mean +/- SE for n = 6 samples from two biological replicates. 
 
within AF1b of ARGal4 and assessed the impact on transcriptional activity (Figure 
3.6). While deletion of the full AF1b domain reduced androgen-independent 
ARGal4 activity, none of the tiling deletions appeared to have a significant impact 
in the absence of androgens. On the other hand, deletion of three independent 
segments between amino acids 273 and 360 inhibited androgen-dependent AR 
activity ~40-50%. Taken together, these data demonstrate that the AR AF1b 
domain harbors significant intrinsic transcriptional activity in prostate cancer cells 
and is required for full activity of the TAU1 domain.  
 
Constitutively active AR splice variants differentially utilize NTD transactivation 
domains compared with full-length AR.  
 Given the emerging role of pathologic AR variants (ARV) in clinical 
prostate cancer [68,90,126], it is critical to develop a functional understanding of 
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the role of each of the known NH2-terminal transcriptional activation domains 
and how they differ in the context of full length versus truncated AR. Since the 
regulatory COOH-terminal domain is deleted in ARV [80,92,95], the dynamics 
and regulation of AR transcriptional activation are likely to be altered in cells 
expressing ARV. This raises the important question of whether AR TAU1 and -5 
function equivalently in full-length AR compared with ARV. Previous studies of 
full-length AR in both androgen-dependent and CRPC cell lines revealed that 
TAU1 deletion completely inhibited AR transcriptional activity [73]. On the other 
hand, TAU5 deletion inhibited only androgen-independent AR activity, whereas 
AR activity was significantly enhanced in the presence of androgen [71,73]. To 
test the impact of TAU5 deletion on ARV activity in LNCaP and C4-2 cells, we 
ablated endogenous AR expression with siRNA and co-transfected with siRNA-
resistant full-length AR, AR-V7 (also referred to as AR3 or 1/2/3/CE3), or AR-
fl/AR-V7 in which TAU5 had been deleted (Figure 3.7). Expression of AR-V7 
elicited strong, constitutive AR activity that was insensitive to androgen, whereas 
AR-fl was only active in the presence of mibolerone. Deletion of TAU5 in AR-V7 
potently inhibited transcriptional activity under all conditions, whereas TAU5 was 
only required for AR-fl activity in the absence of ligand and enhanced AR-fl 
activity in the presence of androgen. 
 To further assess the utilization of NTD transcriptional activation domains 
by ARV, we generated AR-V7 isoforms in which TAU1, AF1a, AF1b, and TAU5 
had been deleted (Figure 3.8). When expressed in DU 145 cells, deletion of 
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Figure 3.7: LNCaP and C4-2 cells were transfected with -5746 PSA-LUC and the 
indicated siRNA-resistant AR constructs, then treated overnight with 1 nM 
Mibolerone or vehicle control. Cells were then lysed and subjected to luciferase 
assay. Bars represent mean +/- SE of n = 6 samples pooled from two 
independent experiments. 
 
TAU1 resulted in ~90% reduction in ARV transcriptional activity, similar to the 
effect of TAU1 deletion in previous studies [73]. Deletion of AF1a or AF1b 
inhibited AR-V7 activity by 45% and 60% respectively, again suggesting a critical 
role for AF1b in AR transcriptional activity. TAU5 deletion resulted in 
approximately 50% inhibition of AR-V7 activity. In LNCaP cells, deletion of AF1a, 
AF1b, and TAU5 inhibited AR-V7 activity on the order of 30% (AF1a) to 70% 
(AF1b and TAU5). Paradoxically, however, deletion of TAU1 doubled AR-V7 
activity in this model. It has been previously suggested that ARV function by 
heterodimerizing with AR-fl and chaperoning it to the nucleus in the absence of 
76 
 Figure 3.8: DU 145 and LNCaP cells were transfected with 4xARE-LUC or -5746 
PSA-LUC, respectively, and the indicated siRNA-resistant AR constructs. Cells 
were treated overnight with 10 μM enzalutamide (ENZ) or vehicle control. Cells 
were then lysed and subjected to luciferase assay. Bars represent mean +/- SD 
of n = 3 samples representative of two independent experiments. * = P < 0.05, ** 
= P < 0.01 relative to CE3. 
 
androgen, thus allowing for perpetuation of AR-fl signaling under castrate 
conditions [66]. To test if this might explain the effect of AR-V7∆TAU1 in LNCaP 
cells, we treated LNCaP with enzalutamide, which inhibits AR-fl nuclear 
translocation and DNA binding [36]. Treatment with enzalutamide had no effect 
on the transcriptional activity of AR-V7 or any of the deletion mutants (Figure 3.8, 
gray bars), suggesting that AR-fl is not contributing to AR-V7 isoform activity in 
this experiment. Taken together, these data indicate differential utilization of AR 
NH2-terminal transcriptional activation domains by ARV compared to full-length 
AR, and that the presence or absence of androgen influences the function of 
these domains in AR-fl. Furthermore, the role of TAU1 in ARV transcriptional 
activity may be cell-line dependent, whereas TAU5 is a critical mediator of ARV 
activity in all cell lines tested. Finally, these data suggest that AF1b plays a 
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critical, previously under-appreciated functional role in both AR-fl and ARV 
transcriptional activity. 
 
DISCUSSION 
 
 In this study, we performed biochemical assays to further define the 
activity and molecular dynamics of the AR TAU1 domain in human PCa cells 
using a Gal4-based reporter system. We demonstrated that, while the 
178LKDIL182 motif is required for full TAU1 activity, a peptide encompassing the 
LKDIL motif does not completely account for the transcriptional activity of AR 
TAU1 in LNCaP PCa cells. Our data also suggest a prominent role for AF1b in 
mediating AR transcriptional activity, which is supported by the observation of 
robust intrinsic transcriptional activity in LNCaP and 293T cells. However, we 
were not able to nominate discrete regions of AF1a or AF1b that could account 
for their respective transactivation functions. Rather, internal deletions produced 
seemingly equivalent intermediate effects, perhaps due to disruption of 
uncharacterized structural elements. Finally, we show that NTD transcriptional 
activation domains are differentially utilized by truncated ARV compared with full-
length AR, suggesting that the presence or absence of the COOH-terminal 
domain may have an effect on the molecular dynamics of the NTD. 
 Short, amphipathic helices have been shown to play a critical role in AR 
NTD function [2,71,72,80,133]. Previous studies of TAU1 and its constituent 
domains concluded that the 178LKDIL182 motif in AF1a was the primary driver of 
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TAU1 transcriptional activity. Our data support the role of the LKDIL motif as a 
major player in TAU1 transcriptional activity in human AR. However, in contrast to 
previous studies, our peptide rescue experiments indicated that the LKDIL motif 
only accounts for approximately half of AR TAU1 transcriptional activity. To this 
end, it should be noted that our study was conducted with an ARGal4 hybrid in AR-
positive human prostate cancer cells, whereas previous studies were modeled 
with ectopically-expressed AR in AR-null, non-prostate cell lines 
[19,70,72,75,128,132-134]. Furthermore, we demonstrated that AF1b harbors a 
high degree of intrinsic transcriptional activity in our ARGal4 model, suggesting a 
more prominent role in AR transcriptional activity than previously appreciated. 
Problematically, standard approaches to biochemical dissection of the intrinsically 
disordered NTD, e.g. small internal deletions and promoter tethering 
experiments, does not appear to be an optimal approach to studying the 
dynamics of AR transcriptional activation. Intrinsically disordered proteins, of 
which the AR is an example, have been shown to rely on allosteric coupled 
binding and folding responses with transcriptional co-regulators in order to 
mediate their activity [135,136]. Internal deletions within protein interaction 
domains, therefore, may disrupt the biophysical properties of the domain as a 
whole rather than providing insight into the regulation of a specific region. 
Similarly, promoter tethering of small fragments of the NTD would likely not 
recapitulate the full allosteric binding elements. These challenges and their 
implications for future translational research on AR transcriptional activation 
domains will be discussed in more detail in the next chapter. 
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 Previous studies have shown that the TAU5 domain of the AR NTD is 
differentially utilized in the presence or absence of androgens in full-length AR 
[71,73]. Whereas deletion of TAU5 in the full-length AR leads to increased activity 
in the presence of androgens, the same deletion is inhibitory when androgens 
are withdrawn. This raises the question of whether the absence of the regulatory 
CTD, such as in AR splice variants, may affect the transcriptional activation 
dynamics of the NTD. Our data demonstrate that deletion of TAU5 in AR-V7 
mimics the latter scenario, suggesting that TAU5 is critical for full transcriptional 
activity of AR splice variants. On the other hand, TAU1 activity in AR-V7 appears 
to be more context-dependent. TAU1 deletion enhanced V7 activity in AR-
expressing LNCaP cells, but is significantly inhibitory in AR-null DU145 cells. This 
may be due to 1) differences in AR co-regulator expression between the two cell 
lines, or 2) a promoter-dependent effect borne out by the use of a concatenated 
4x-androgen response element-driven reporter in DU 145 vs. a PSA enhancer-
driven reporter in LNCaP. Deletion of AF1a is inhibitory in both cell lines, though 
to a much lesser degree in LNCaP cells, particularly when contrasted to the 
effect of AF1a deletion in the full-length AR. Finally, deletion of AF1b was potently 
inhibitory in LNCaP cells, but less so in DU145. Taken together, these data 
demonstrate that AR variants differentially utilize NTD transcriptional activation 
domains, and that the activity of these domains may be context-dependent 
depending on the expression of transcriptional co-regulators or 
promoter/enhancer context. Future experiments should address these questions 
using stably transfected cell lines to characterize the binding partners associated 
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with each of these domains, and whether the co-regulatory cohort differs 
significantly in cells that express AR-fl, ARV, or are AR-null. We will discuss this 
strategy and its potential applications in Chapter 4. 
 In summary, we confirm that short, amphipathic helices are central to the 
transcriptional activity of the AR NTD, but that these helices are likely not 
responsible for the full level of AR NTD transcriptional activity. We also report 
robust intrinsic transcriptional activity of AF1b which is required for AR 
transcriptional activity, and that the utilization of the TAU1, AF1a, AF1b, and 
TAU5 domains differs between full-length AR and truncated AR variants. The 
utilization of these domains may also be context dependent, particularly with 
regard to the transcriptional coregulatory cohort expressed in the cell. Taken 
together, these data provide new insights into the regulation and activity of the 
AR NTD, which remains an attractive target for therapeutic intervention. Future 
translational inquiry into NTD dynamics should be informed by studies of other 
intrinsically disordered proteins, which will be discussed in the next chapter.  
 
MATERIALS AND METHODS 
Cell Culture  
LNCaP, C4-2, DU 145, and 293T cell lines were obtained from ATCC and 
maintained in medium and serum as directed by ATCC protocols. The ATCC 
validates the authenticity of these cell lines via short tandem repeat (STR) 
analysis. Cells were cultured in a 37o C incubator with 5% CO2 for no longer than 
15 passages after resuscitation of frozen stocks. 
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 Reagents 
Mibolerone (MIB) was purchased from Sigma. Enzalutamide (ENZ) was 
purchased from Selleck Chemicals. Superfect and Lipofectamine 2000 
transfection reagents were purchased from Life Technology. 
 
Plasmids  
Plasmids encoding human AR (p5HBhAR-A), ARGal4, ARGal4∆TAU1, 
ARGal4∆TAU5, sPSA-Luciferase (also referred to as PSAenh(ARE)-LUC), and 
sPSAGal4-Luciferase (also referred to as PSAenh(GAL4)-LUC) have been 
described [45]. SV40-Renilla and pG5-Luciferase were purchased from 
Promega. The Gal4 DBD expression plasmid (pM) was purchased from 
Clontech. Gal4-TAU1 (AR a.a. 101-360) has been previously described [121].  
Tiling deletions within AF1a (AR a.a. 101-211) and AF1b (AR a.a. 251-
360), as well as deletions of the full AF1a and AF1b domains, were prepared by 
introducing in-frame BssHII recognition sites into the ARGal4 expression vector 
using a Stratagene QuikChange site-directed mutagenesis kit (New England 
Biolabs) with custom mutagenic primers as listed in Table 3.2. Mutagenized 
plasmids were then digested with BssHII, ligated, and transformed into 
ultracompetent E. coli. Deletions were verified by restriction digest. 
Gal4 tethering of AF1a and AF1b was performed by PCR amplification of the 
AF1a and AF1b domains with mutagenic primers that introduced in-frame 5’ 
EcoRI and 3’ HindIII recognition sites (AF1a EcoR1 Fwd: 
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GGTTCTCCCgAAttCCATCGTAGAGGCCCC; AF1a HindIII Rev: 
GGGAGCCCCGCAaGCtTCCCTCGCTCTCCC; AF1b EcoRI Fwd: 
GTGTCGGTGTCCATGGAATTCGGTGTGGAGGCG; AF1b HindIII Rev: 
CAGTGGAAGCTTGTAGTAGTC). Amplicons were digested with EcoR1 and 
HindIII, and then cloned into EcoRI/HindIII-digested pM. Insertions were verified 
by restriction digest. 
 
Table 3.2: Mutagenic Primer Sequences for TAU1 Sub-domain Deletions 
Amino 
Acid 
Position 
Forward/Reverse Mutagenic Primer Sequences  
(mutated residues noted in lowercase lettering) 
101/102 F: CAAGCCCATCGTAGAGcgCgCACAGGCTACCTGGTC  
R: GACCAGGTAGCCTGTGcGcgCTCTACGATGGGCTTG 
124/125 F: CGGGACCTCACGGTGGcGCgCTCTCCAACGCAGGGTCTC 
R: GAGACCCTGCGTTGGAGAGcGCgCCACCGTGAGGTCCCG 
136/137 F: CTCGGACGAGCCGCCGcGcgCGCCAGCAAGGGGCTG 
R: CAGCCCCTTGCTGGCGcgCgCGGCGGCTCGTCCGAG 
150/151 F: CAGCTGCCAGCACCTgCgcgCGAGGATGACTCAGCTGCC 
R: GGCAGCTGAGTCATCCTCGcgcGcAGGTGCTGGCAGCTG 
169/170 F: CTGGGCCCCACTTTCgCgcGCTTAAGCAGCTGCTCC 
R: GGAGCAGCTGCTTAAGCgcGcGAAAGTGGGGCCCAG 
185/186 F: GACATCCTGAGCGAGGCgcGCACCATGCAACTCCTTCAG 
R: CTGAAGGAGTTGCATGGTGCgcGCCTCGCTCAGGATGTC 
211/212 F: CAGCAGCAGCGGGAGAGCGcGcGAGGCCTCGGGGGCTC 
R: GAGCCCCCGAGGCCTCgCgCGCTCTCCCGCTGCTGCTG 
251/252 F: 
GCAGTGTCGGTGTCCATGGcgCgcGGTGTGGAGGCGTTGGAG 
R: 
CTCCAACGCCTCCACACCgcGcgCCATGGACACCGACACTGC 
272/273 F: GGGGATTGCATGTACGCgCgcCTTTTGGGAGTTCCACCC 
R: GGGTGGAACTCCCAAAAGgcGcGCGTACATGCAATCCCC 
301/302 F: 
CTGCTAGACGACAGCGCgcGCAAGAGCACTGAAGATACTGC 
R: GCAGTATCTTCAGTGCTCTTGCgcGCGCTGTCGTCTAGCAG 
328/329 F: GGCGAGAGCCTAGcgcGCTCTGGCAGCGCTGCAGCAGGG 
R: CCCTGCTGCAGCGCTGCCAGAGCgcgCTAGGCTCTCGCC 
360/361 F: GCACTGGACGAGGCAGCTGCGcgCCAGAGTCGCGACTAC 
R: GTAGTCGCGACTCTGGcgCGCAGCTGCCTCGTCCAGTGC 
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 Gal4 tethering of AF1a fragments was performed by synthesizing 
complementary oligonucleotides, which when annealed would form dsDNA 
cassettes encoding short peptide sequences (approximately 10-20 amino acids  
 
Table 3.3: Synthetic AF1a Oligonucleotides  
AF1a 
Region 
Oligo Sequences Peptide Sequence 
100-125 Fwd: AATTC GGC CCC ACA GGC TAC CTG GTC CTG 
GAT GAG GAA CAG CAA CCT TCA CAG CCG CAG 
TCG GCC CTG GAG TGC CAC CCC GAG TAA A 
 
Rev: AGCTT TTA CTC GGG GTG GCA CTC CAG GGC 
CGA CTG CGG CTG TGA AGG TTG CTG TTC CTC 
ATC CAG GAC CAG GTA GCC TGT GGG GCC G 
QF-
GPTGYLVLDEEQ
QPSQPQSALECH
PE-Stop 
124-137 Fwd: AATTC CCC GAG AGA GGT TGC GTC CCA GAG 
CCT GGA GCC GCC GTG GCC TAA A 
 
Rev: AGCTT TTA GGC CAC GGC GGC TCC AGG CTC 
TGG GAC GCA ACC TCT CTC GGG G 
QF-
PERGCVPEPGAA
VA-Stop 
136-152 Fwd: AATTC GTG GCC GCC AGC AAG GGG CTG 
CCG CAG CAG CTG CCA GCA CCT CCG GAC TAA A 
 
Rev: AGCTT TTA GTC CGG AGG TGC TGG CAG CTG 
CTG CGG CAG CCC CTT GCT GGC GGC CAC G 
QF-
VAAASKGLPQQL
PAPPD-Stop 
151-171 Fwd: AATTC CCG GAC GAG GAT GAC TCA GCT GCC 
CCA TCC ACG TTG TCC CTG CTG GGC CCC ACT 
TTC CCC GGC TAA A 
 
Rev: AGCTT TTA GCC GGG GAA AGT GGG GCC CAG 
CAG GGA CAA CGT GGA TGG GGC AGC TGA GTC 
ATC CTC GTC CGG G 
QF-
PDEDDSAAPSTL
SLLGPTFPG-Stop 
170-187 Fwd: AATTC CCC GGC TTA AGC AGC TGC TCC GCT 
GAC CTT AAA GAC ATC CTG AGC GAG GCC AGC 
TAA A 
 
Rev: AGCTT TTA GCT GGC CTC GCT CAG GAT GTC 
TTT AAG GTC AGC GGA GCA GCT GCT TAA GCC 
GGG G 
QF-
PGLSSCSADLKDI
LSEAS-Stop 
186-210 Fwd: AATTC GCC AGC ACC ATG CAA CTC CTT CAG 
CAA CAG CAG CAG GAA GCA GTA TCC GAA GGC 
AGC AGC AGC GGG AGA GCG AGG TAA A 
 
Rev: AGCTT TTA CCT CGC TCT CCC GCT GCT GCT 
GCC TTC GGA TAC TGC TTC CTG CTG CTG TTG 
CTG AAG GAG TTG CAT GGT GCT GGC G 
QF-
ASTMQLLQQQQ
QEAVSEGSSSGR
AR-Stop 
 
84 
in length) within AF1a, with 5’ and 3’ sticky ends resembling DNA digested with 
EcoRI and HindIII, respectively (Table 3.3). An in-frame stop codon was included 
upstream of the 3’ HindIII end to restrict translation of the resulting peptide. 
dsDNA cassettes were cloned into EcoRI/HindIII-digested pM. Insertions were 
verified by restriction digest. 
 
Cell Transfection 
LNCaP cells were transfected via single-pulse electroporation as 
previously described [45]. C4-2 and DU 145 cells were transfected with Superfect 
reagent (Qiagen) according to manufacturer specifications. 293T cells were 
transfected with Lipofectamine 2000 (Life Technologies) according to 
manufacturer specifications. Treatment of transfected cells with androgen or 
enzalutamide was performed for 24 h in serum-free medium where indicated.  
 
Dual Luciferase Assays 
Transfected cells were lysed in 1X Passive Lysis Buffer (Promega) and 
subjected to dual luciferase assays using a Dual Luciferase Assay Kit (Promega) 
as previously described [45]. 
 
Western Blot 
Western blotting was performed as previously described [65]. Antibodies 
used in this study were: anti-AR N-20 (Santa Cruz), anti-Gal4 DBD (Santa Cruz), 
anti-ERK2 D-2 (Santa Cruz), anti-β-Actin (Sigma), and HRP-conjugated 
85 
secondary antibodies for Mouse- or Rabbit IgG (Santa Cruz). 
 
Data Analysis and Statistics 
All statistical comparisons were made using the two-tailed Student’s t-Test 
with a P value of 0.05 or less considered significant. Asterisks in figures denote 
levels of statistical significance, such that * = P < 0.05; ** = P < 0.01; *** = P < 
0.001; **** = P < 0.0001; n.s. = not significant. Statistics are displayed relative to 
the vehicle/vector control unless otherwise noted by lines/bars showing specific 
comparisons in the figure. 
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CHAPTER 4 
THERAPEUTIC TARGETING OF THE ANDROGEN RECEPTOR IN PROSTATE 
CANCER: PAST, PRESENT, AND FUTURE 
 
OVERVIEW  
 
 Prostate cancer (PCa) is common in western men, and represents a 
significant clinical and financial burden in the US. The emergence of bilateral 
orchiectomy to induce a castrate level of testosterone in prostate cancer patients 
marked the advent of the first targeted cancer intervention, and led to the 
identification of the androgen receptor (AR) as the primary therapeutic target in 
PCa. Given the ongoing reliance of PCa on AR signaling, even after resistance to 
hormone-based therapy has developed, the AR continues to be an attractive 
therapeutic target. However, despite a long history of research, curative 
interventions for advanced prostate cancer have yet to be developed and drug 
resistance continues to pose a significant clinical problem. The mutability of the 
AR ligand binding domain, as well as the lack of structural data for the 
intrinsically disordered NH2-terminal transactivation domain (NTD), pose 
considerable challenges for the rational design of potent anti-AR therapies. Here, 
we discuss a brief history of AR targeting in PCa, as well as provide a 
perspective on possible future avenues of research that could lead to the 
development of new AR-targeted therapeutics. 
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ANDROGEN DEPRIVATION: THE CENTRAL THEME OF PCa THERAPY  
 
 Androgen signaling, and the inhibition thereof, has long been recognized 
as a critical component in the treatment of advanced and metastatic prostate 
cancer (PCa) [122,123]. Indeed, the critical role of testosterone in the 
progression of PCa was established in 1941 [137], well in advance of the advent 
of molecular medicine or even the discovery of the androgen receptor (AR) itself. 
By performing bilateral orchiectomy to remove the testes, and thus the source of 
most of the testosterone in the body, Huggins and Hodges noted dramatic 
reductions in serum phosphatases, which were known indicators of poor 
prognosis. Administration of estrogenic hormones caused reductions in the 
serum concentration of these same phosphatases, whereas administration of 
testosterone to patients caused their expression to increase. In effect, this 
discovery established androgen ablation as the first targeted cancer intervention, 
and laid the groundwork for decades of research into the role of androgens in the 
natural history of PCa. Today, this approach is known as androgen deprivation 
therapy (ADT), and it is the cornerstone on which therapeutic intervention for 
advanced and metastatic PCa is built [122,123]. 
 Despite this early advance, PCa proved to be a tenacious disease. 
Nitrogen mustards and other cytotoxic chemotherapeutics which had shown 
promise in cancers such as leukemia and lymphoma were demonstrated to be 
ineffective treatments for prostate cancer [138]. This could potentially be 
attributed to the specialized metabolic state of prostate epithelial cells [81] as well 
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as the relatively slow growth rate of prostatic tumors compared to other cancers 
[139,140]. Microtubule inhibitors appear to be the exception, extending overall 
survival and enhancing quality of life in patients with CRPC [141]. Initially, the 
effectiveness of taxanes in CRPC was attributed inhibition of AR nuclear 
translocation along the microtubule network [142], though a recent study 
demonstrated that taxane action in PCa cells is independent of AR localization at 
pharmacologic doses [143]. Docetaxel has been shown to provide a modest, ~2 
month survival benefit as a single agent therapy for metastatic CRPC [144]. More 
recently, a multi-center Phase III clinical trial concluded that the addition of 
docetaxel to ADT in hormone-naïve patients resulted in overall survival (~13.5 
months) and time to progression (~6 months) benefits compared with ADT alone 
[145]. Cabazitaxel is a second-generation microtubule inhibitor with efficacy in 
patients who have progressed on docetaxel, extending overall survival by 
approximately 2 months [146]. Clinical trials assessing the functionality of 
cabazitaxel in the chemotherapy-naïve setting are currently under way. 
Nevertheless, even with the modest success of taxane-based chemotherapy, the 
general dearth of viable chemotherapeutic options that target pathways other 
than AR remains an ongoing problem in the management of clinical PCa. 
Medical treatment of metastatic PCa via the AR, however, has persisted 
as an active area of research [123]. With the dawn of the molecular biology age 
in the late 1970’s to the early 1980’s and the concomitant expansion of our 
understanding of molecular signaling pathways, new avenues were opened to 
increase the therapeutic arsenal for targeting AR signaling. Gonadotropin-
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releasing hormone agonists (GnRH-A), such as leuprolide and gosrelin, were 
shown to induce a castrate state without surgical removal of the testes [147]. 
These drugs function by stimulating a continuous release of luteinizing hormone 
from the pituitary, which stimulates testosterone synthesis by the testes. This 
surge in hormone secretion triggers a negative feedback loop, with cessation of 
testosterone production by the testes and nadir of circulating androgens as an 
endpoint [148]. This loop reduces serum testosterone to an equivalent level as 
orchiectomy over time, and medical castration was shown to be indistinguishable 
from surgical castration in terms of clinical outcome [149]. 
Anti-androgens, or AR antagonists, represented another critical step 
forward in AR-targeted therapy [83]. Rather than prevent the synthesis of 
androgens, drugs such as nilutamide [150], flutamide [151], and bicalutamide 
[152] were designed to bind competitively to the AR ligand binding domain (LBD) 
and inhibit the association of the AR with testosterone and dihydrotestosterone, 
thus preventing AR signaling. The ability to target both androgen production and 
the action of androgens on the AR led to the hypothesis that combined (or 
maximal) androgen blockade, i.e. treatment with both castration and an 
accompanying antiandrogen, might produce a stronger, more durable 
suppression of PCa growth and progression. Despite promising initial results, 
meta-analysis of randomized clinical trials demonstrated only minor differences in 
clinical outcome between patients receiving single-therapy ADT and those 
receiving combinatorial treatment [153]. Thus, while the arsenal of available 
intervention strategies has expanded significantly since Huggins and Hodges’s 
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initial discovery, the principles of PCa therapy have changed little in the ensuing 
75 years. 
 
SECOND-GENERATION ADT AND THE CONTINUING CHALLENGE OF 
CASTRATION RESISTANCE 
 
While both ADT and AR blockade have proven to be effective intervention 
strategies, hormone resistance poses a critical problem in the management of 
late-stage PCa [82,84,126]. After an initial response, patients receiving 
pharmacological treatment for PCa inevitably experience a transition from the 
initial, androgen-dependent tumor state to castration resistant (CRPC) disease 
[124]. Initially, CRPC was thought to be caused by the complete loss of androgen 
receptor expression or other AR bypass pathways. However, ongoing research 
has shown that loss of AR expression is a relatively rare event in the natural 
history of PCa. Current data support a continuing role for AR in PCa and CRPC 
progression as both a metabolic master regulator [81] as well as a pro-survival 
factor [82]. A multitude of molecular mechanisms have been identified that 
contribute to ongoing AR function in late-stage CRPC [1,127,154]. Chief among 
these is amplification of the AR gene locus leading to increased AR expression 
[155], which allows for hypersensitivity to castrate levels of androgen hormones. 
Further, bicalutamide has been shown to activate AR activity in the context of 
amplified AR [155], and several mutations of critical amino acid residues in the 
AR ligand binding pocket have been identified that allow for continuous AR 
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activation in the context of androgen deprivation or blockade [156-158]. Recently, 
alternate androgen synthesis pathways in the adrenal glands as well as in 
prostate cancer tissues have been shown to be up-regulated in CRPC, thus 
circumventing the effect of ADT by increasing local androgen concentration 
[91,154]. These mechanisms, as well as myriad alterations in the genetic 
landscape of advanced PCa [64], allow for the ongoing survival and proliferation 
of prostate tumors. 
Given the propensity of PCa to develop into a castration resistant state 
with continued reliance on AR signaling for survival and proliferation, renewed 
emphasis was placed on developing compounds that could overcome the 
challenges posed by AR amplification, mutation, and peripheral androgen 
synthesis. These efforts have been successful, and recent studies have 
demonstrated a significant clinical benefit for the second-generation ADT 
therapeutics enzalutamide [36,39,85] and abiraterone [37,38,87,159]. 
Enzalutamide is a non-steroidal anti-androgen that was developed using 
bicalutamide as a molecular scaffold and which boasts a higher affinity for the AR 
LBD as well as an enhanced ability to inhibit AR transactivation. Enzalutamide 
produced a statistically significant survival benefit in men with CRPC, further 
emphasizing the ongoing role of AR in late-stage metastatic PCa. Abiraterone, on 
the other hand, functions to irreversibly inhibit the CYP17A1 aromatase enzyme 
responsible for conversion of adrenal hormones to testosterone precursors [159]. 
When combined with conventional ADT, abiraterone induces a so-called “super-
castrate” state by further suppressing the levels of circulating androgens, as well 
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as preventing intratumoral androgen synthesis. Interestingly, due to its steroid 
hormone-like structure, abiraterone also directly binds and inhibits the AR LBD as 
an antagonist in vitro [160]. Abiraterone was recently shown to extend median 
time to progression in CRPC patients [37,38,87] and, along with enzalutamide, 
has been incorporated into the clinical repertoire. However, the onset of 
resistance to these interventions in men with previous exposure to hormone 
ablation is rapid, with a median time to progression of ~4-5 months [38,39]. 
Furthermore, a subset of patients in these studies harbored disease with de novo 
resistance to enzalutamide and abiraterone, and exhibited no response to 
treatment. Since enzalutamide and abiraterone target the same processes as 
front-line ADT (i.e., androgen production and AR binding), it is thought that prior 
exposure to hormone therapy may blunt the effect of these new, more effective 
interventions by priming PCa to tolerate lower levels of AR activity. Clinical trials 
are currently underway to determine the efficacy of enzalutamide and abiraterone 
in hormone-naïve patients, with the anticipation that more aggressive front-line 
therapy may produce more durable clinical responses. 
 AR splice variants (ARV) represent one possible mechanism by which 
CRPC could circumvent ADT and continue to progress in patients receiving 
hormone therapy [80,127]. As previously discussed, ARV lack the regulatory 
COOH-terminal ligand binding domain, and can be generated by alternative 
splicing of the AR mRNA, as well as by genomic rearrangements of the AR locus 
(see Chapter 1). Thus, ARVs are constitutively active transcription factors that 
are wholly insensitive to conventional ADT interventions. More recently, analysis 
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of ARV expression in clinical PCa samples revealed a higher incidence of 
expression in men treated with hormone therapy, with ARV expression detected 
in 39% of patients treated with enzalutamide and 19% of patients treated with 
abiraterone [126]. This finding suggests that ARV expression may be more 
intricately involved in PCa progression as opposed to tumorigenesis. Overall, 
these data highlight a critical unmet need in the clinic: a method by which AR 
transcriptional activity can be targeted and inhibited directly via the NH2-terminal 
transcriptional activation domains. 
 
DISORDER IN THE AR NTD: THE NEXT FRONTIER 
  
 Given the critical role of the NTD in AR signaling, we are presented with 
the likely conclusion that durable inhibition of AR in PCa may only be feasible by 
inhibiting the NTD directly. This has proven to be a persistent challenge, as 
structural data for the domain has remained elusive due to its intrinsically 
disordered biophysical properties [76,116,117]. Intrinsically disordered regions 
(IDR) and intrinsically disordered proteins (IDP) are common in the human 
proteome, including well-known cell cycle and transcriptional regulators such as 
p53, p21, p27, CREB, and RELA [129].  These proteins use their IDR to mediate 
a broad range of functions that can be fine-tuned via amphipathic interactions or 
post-translational modifications, functioning as a molecular rheostat or signaling 
threshold detector within the cell. The lack of tertiary structure in IDR allows for 
easy access to clustered modifiable sites by kinases, phosphatases, and E3-
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ligases [161], and many parallels can be drawn with the known biophysical and 
biochemical properties of the AR. For example, the AR NTD contains a multitude 
of post-translationally modified sites within the disordered NTD [162,163]. Thus, 
intrinsic disorder is central to the function of these proteins, allowing for rapid 
fine-tuning of target activity, stability, or protein-protein interactions.  
However, the lack of structural specificity in IDR, as well as a high degree 
of motif conservation and repetition between different IDP, presents a major 
challenge to developing molecular interventions with a high degree of specificity 
for a particular IDP. EPI-001 is a quintessential example of the hazards of 
targeting IDR, particularly with covalent modifiers (Chapter 2). While local pH 
influence allows for some selectivity in the drug’s ability to covalently modify 
proteins, the lack of specificity for the AR NTD leads to myriad off-target 
interactions within the cell. Without a highly nuanced understanding of the IDR in 
question, such an approach to IDR inhibition may not be feasible. Furthermore, 
conventional biochemical approaches to assessing the function of protein 
interaction domains may be ineffective for assessing the architecture and 
function of IDR, due to the inevitable disruption of unknown structural elements 
and allosteric binding interfaces (Chapter 3). Due to the nature of IDR, dissecting 
and separating individual components from the context of the IDR as a whole is 
not a viable strategy to characterize their activity. Rather, a more nuanced 
computational approach to this question may be required, as has been 
performed for the glucocorticoid receptor [164]. 
Regardless, deletion of AR TAU1, AF1a, AF1b, and TAU5 has revealed 
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critical roles for each domain under various conditions [2,71,73]. Thus, 
enumeration of the binding partners responsible for interacting with and imposing 
structure upon each of these domains, a process known as coupled folding and 
binding [135,136,165], will be a critical step in developing therapies that target 
the AR NTD directly. Determination of the differences in binding partner 
recruitment by the NTD in response to the presence or absence of androgens, 
and more importantly the presence or absence of the regulatory LBD itself, will 
also play a key role. Finally, in-depth characterization of AR NTD post-
translational modifications and their effects, if any, on coactivator recruitment will 
be vital to this effort. 
 
ACTIONABLE FEATURES OF THE AR NTD AS THERAPEUTIC TARGETS  
 
Though many IDRs are expressed in a tissue-specific fashion via 
mechanisms such as alterative splicing [130,131], many retain common 
sequence elements and/or share binding partners with other IDP [129], and thus 
the discussion of how to therapeutically target the AR NTD should stem from its 
commonalities with other known IDP. For example, AR is well known to rely on 
interactions with CBP/p300 chromatin remodeling enzymes, as well as p160 
nuclear receptor coactivators such as the SRC family [13]. CBP/p300 and p160 
proteins have also been implicated in binding to other IDP such as CREB [166]. 
CBP binds via a molten globular KIX domain to the phosphorylated kinase-
inducible domain (pKID) of CREB, an interaction in which both partners impose 
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structure upon one another through coupled folding and binding. CBP is then 
able to recruit p160 coactivators through its nuclear coactivator binding domain. 
These events work in concert to provide a ternary structure and scaffold upon 
which the transcriptional machinery assembles, and it is tempting to speculate 
that AR may interact with these binding partners in a similar fashion.  
IDP are also characterized by an ability to interact with a wide variety of 
binding partners by virtue of transient, dynamic interactions through so-called 
“fuzzy” sites [167,168]. Fuzzy interactions are characterized by a lack of coupled 
folding and binding. Rather, these interactions are characterized by persistence 
of disorder throughout the interaction, and function to mediate interactions 
between multiple binding partners [169]. The AR has been shown to interact with 
numerous coregulatory proteins [13], and the ability to form low-affinity or 
allosteric interactions with a broad cohort of partners as well as higher-affinity 
coupled folding and binding responses may explain this property. 
The presence of pre-formed helices in IDR is another mitigating factor in 
protein-protein interactions, though the precise role they play in regulation of 
transcription factor function is currently a matter of some debate. Some studies 
have indicated that these helices are required for recruitment of coactivators 
[170-172], whereas others have suggested that they are ultimately dispensable 
for IDR function or can even inhibit complex formation [173,174]. Regardless, the 
AR harbors a number of short, amphipathic helices that have garnered much 
interest as potential mediators of transcriptional activity, namely 23FNQLF27, 
178LKDIL182, and 435WHTLF439. LKDIL is located in the TAU1 AF1a region and 
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appears to be required for full AR transcriptional activity (Chapter 3), and 
mutation to LKDNN significantly impairs AR transcriptional activity. WHTLF has 
been more thoroughly characterized, and is known to be required for TAU5-
mediated activity [71]. FNQLF does not map to a known transcriptional activation 
domain, but has been implicated in intramolecular interactions between the AR 
NTD and AF-2 protein binding interface of the COOH-terminal domain [19]. The 
individual contribution of each of these helices in the function of the AR NTD as 
an IDR is currently unknown. However, amphipathic F/LxxLL/F, nuclear receptor 
box-type motifs [175,176] have been strongly implicated in interactions between 
p160 co-regulators and their binding partners [177], as well as a recently-
characterized interaction between RelA and CBP/p300 [172]. In the latter study, 
mutation of the hydrophobic residues significantly attenuated the ability of RelA to 
interact with CBP, with concomitant inhibitory effects on NF-κB transcriptional 
activity. Taken together, these data imply that amphipathic helices in IDR have 
the potential to function as anchor points that enhance the fidelity of coupled 
folding and binding responses, and their interactions with co-regulatory binding 
partners should be considered putative targets for therapeutic intervention. 
 
FUTURE DIRECTIONS 
 
The AR NTD presents an intriguing challenge for translational PCa 
research. Decades of research into the mechanisms underlying AR 
transcriptional activity have identified many functional features within the NTD, 
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but how these features work in concert to fine-tune AR transcriptional output 
remains an elusive question. New findings on the role and regulation of IDR has 
the potential to shine a light into the inner workings of the NTD, but a number of 
critical questions are yet to be addressed with regard to the AR in particular. 
Perhaps the most pressing need from this standpoint is a comprehensive, 
mechanistic understanding of the specific function of each of the NH2-terminal 
transcriptional activation domains. Elucidation of the co-regulatory cohort 
associated with each functional domain in the NTD, as well as the conditions 
under which these associations exist, will significantly aid this effort. One possible 
avenue of exploration may include rapid immunoprecipitation and mass 
spectrometry of endogenous proteins (RIME) [178,179] performed on cells 
expressing wild-type and mutant versions of the AR, to match specific AR NTD 
mutations with loss of specific co-regulator associations. Single-molecule 
fluorescence resonance energy transfer (smFRET) could then be used in 
conjunction with RIME data and mutagenic scanning of the domains to identify 
proteins that interact directly with AR, as well as the structural features of the AR 
that mediate that interaction. 
Direct AR-binding partners identified via the methods described above 
would serve as attractive targets for small-molecule peptidomimetic inhibitors that 
could be modeled after putative anchor regions, such as the amphipathic helices 
present in the AR NTD. Alternatively, peptidomimetics modeled after structural 
elements of AR binding partners that trigger a conformational or allosteric change 
in the AR NTD and render it incompetent for complex formation or transcriptional 
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activity may present another alternative. Efforts in rational drug design have met 
with success following both of these strategies in IDP [180,181], suggesting that 
such directions may be feasible for the design of AR NTD inhibitors as well. 
Recently, Ravindranathan and colleagues reported the development of an 
LXXLL-like peptidomimetic compound, D2, which effected potent anti-AR activity 
in prostate cancer models [182]. In this case, the drug is targeted against a 
protein-protein interaction with PELP-1 mediated by the COOH-terminal AF-2 
protein binding interface. However, this interface, as well as the ability of D2 to 
inhibit AR activity, is lost with the generation of ARV. Thus, the design of NTD-
targeted interventions of this type remains an unmet need. 
 Computational methods may also provide critical data on the binding and 
folding properties of IDR. Biophysical modeling of inter- and intra-molecular 
interactions between the AR and its binding partners could inform rational drug 
design efforts, particularly if used in concert with molecular and biochemical 
studies as discussed above. By determining likely binding partners and their 
biochemical interfaces with the IDR of the AR NTD, computational modeling 
could provide valuable insight into the biophysical properties of the domain in 
question. Determining the strength of binding to a given domain, e.g. whether the 
proteins engage in coupled folding and binding or in a “fuzzy” interface that may 
be less desirable for therapeutic targeting, will be critical to this effort. Viral 
proteins have been suggested as a possible starting point from which IDR-
inhibiting therapeutics could be designed, due to their evolutionarily-selected 
properties that allow for interaction with a wide variety of proteins in order to 
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hijack host cellular machinery [129,183]. Finally, given the size of the AR IDR and 
the complexity of its multiple transcriptional activation domains, it may be 
necessary to target multiple domains at once. Computational models coupled 
with rational drug design have achieved success in this arena as well [184], and 
this strategy could be applied to prevent AR from engaging in coupled folding and 
binding processes along the length of the NTD. 
 
SUMMARY  
 
 For almost 75 years, the androgen signaling axis has been the primary 
target for therapeutic intervention in advanced and metastatic prostate cancer. 
Though the clinical arsenal has expanded, the principles remain static and 
significant clinical burden stems from the problem of castration resistance. 
Therefore, new approaches to inhibiting AR activity are required to produce 
durable responses in patients with CRPC, particularly in light of the discovery of 
ARV that are insensitive to manipulation of the ligand binding domain. A 
promising target, therefore, lies in the intrinsically disordered but transcriptionally 
active AR NTD. Recent advances in the understanding of how IDRs function in 
human cells, as well as success in rational drug design targeting these regions, 
provides a strong basis for adopting similar strategies to target the AR and its 
transcriptional co-regulatory cohort. Looking ahead, new perspectives on 
lingering questions about NTD regulatory dynamics, coupled with innovative 
experimental approaches to drug design, have the potential to unlock new 
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avenues of translational research to strike a critical blow against prostate cancer. 
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APPENDIX: EPI-001 CHEMICAL SYNTHESIS AND ANALYSIS OF PURITY 
 
 
General. Chemical reagents were typically purchased from Sigma-Aldrich and used 
without additional purification unless noted. Bulk solvents were from Fisher Scientific. 
N,N-dimethylformamide (DMF) was rendered anhydrous by passing through the resin 
column of a solvent purification system (MBraun). Reactions were performed under an 
atmosphere of dry N2 unless noted. Silica gel chromatography was performed on a 
Teledyne-Isco Combiflash Rf-200 instrument utilizing Redisep Rf Gold High 
Performance silica gel columns (Teledyne-Isco). Analytical HPLC analysis was 
performed on an Agilent 1200 series instrument equipped with a diode array detector 
and a Zorbax SB-C18 column (4.6 x 150 mm, 3.5 μm, Agilent Technologies). The 
method started with a 10% CH3CN (with 0.1% trifluoroacetic acid (TFA)) in H2O (0.1% 
TFA), the 10% CH3CN (with 0.1% TFA) was increased to 15% over 2 minutes, increased 
to 20 % over 3 more minutes and then increased to 95% CH3CN (with 0.1% TFA) over 
25 minutes. Nuclear magnetic resonance (NMR) spectroscopy employed a Bruker 
Ascend instrument operating at 500 MHz (for 1H) and 125 MHz (for 13C) at ambient 
temperature. Chemical shifts are reported in parts per million and normalized to internal 
solvent peaks or tetramethylsilane. Mass spectrometry was recorded in positive-ion 
mode on an Agilent MSD SL Ion Trap. 
 
 
(4-hydroxyphenyl)(4-(oxiran-2-ylmethoxy)phenyl)methanone (1). This compound was 
prepared by modification to the previously reported procedure [REF. A1]. To a stirred 
solution of NaH (60% dispersion in oil, 1.453 g, 36.331 mmol) in anhydrous DMF (150 
mL) at 0 °C was added bisphenol A (4.000 g, 16.514 mmol). The reaction was stirred for 
30 min, then tetrabutylammonium iodide (1.220 g, 3.303 mmol) and epichlorohydrin 
(3.24 mL, 41.3 mmol) was added and the reaction was allowed to warm up to room 
temperature (rt) over 12 h. The reaction was quenched with water and extracted with 
ethyl acetate (3 x 50 mL). The organic layer was washed with water (2 x 30 mL), dried 
over Na2SO4, and concentrated in vacuo. The crude mixture was purified by silica gel 
chromatography (gradient CH2Cl2 to 10% EtOAc in CH2Cl2) to afford 1 (0.580 g, 12% 
yield) as a clear foam. 1H NMR (DMSO-d6): δ 9.15 (s, 1H), 7.09 (d, J = 8.5 Hz, 2 H), 6.98 
(d, J = 8.5 Hz, 2 H), 6.83 (d, J = 8.5 Hz, 2 H), 6.64 (d, J = 8.5 Hz, 2 H), 4.26 (dd, J = 
11.5, 2.5 Hz, 1 H), 3.78 (dd, J = 11.0, 6.5 Hz, 1 H), 3.29 (br s, 1 H), 2.82 (t, J = 4.5 Hz, 1 
H), 2.69 (dd, J = 5.0, 2.5 Hz, 1 H), 1.55 (s, 6 H). 13C NMR (DMSO-d6): δ 155.9, 154.9, 
143.2, 140.7, 127.4 (2), 127.3 (2), 114.6 (2), 113.8 (2), 68.8, 49.7, 43.8, 41.0, 30.8 (2). 
MS (m/z) calc’d for C18H20O3 284.1, found 285.1 [M+H]+. 
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(4-(2,3-dihydroxypropoxy)phenyl)(4-(oxiran-2-ylmethoxy)phenyl)methanone (2). This 
compound was prepared as previously described [REF. 1]. To a stirred solution of 1 
(0.493 g, 1.735 mmol) in anhydrous DMF (15 mL) at rt was added K2CO3 (0.480 g, 3.469 
mmol) and glycidol (0.35 mL, 5.20 mmol). The reaction was stirred at 60 °C for 12 h. The 
reaction was cooled to rt, quenched with water and extracted with ethyl acetate (3 x 15 
mL). The reaction mixture was washed with water (2 x 10 mL), dried over Na2SO4, and 
concentrated in vacuo. The crude mixture was purified by silica gel chromatography 
(gradient 10% EtOAc in CH2Cl2 to 50% EtOAc in CH2Cl2) to afford 2 (0.258 g, 41% yield) 
as a clear foam. 1H NMR (DMSO-d6): δ 7.09 (dd, J = 9.0, 7.0 Hz, 4 H), 6.83 (dd, J = 
14.0, 8.5 Hz, 4 H), 4.89 (d, J = 5.0 Hz, 1 H), 4.62 (t, J = 5.5 Hz, 1 H), 4.26 (dd, J = 11.5, 
2.5 Hz, 1 H), 3.94 (dd, J = 9.5, 4.0 Hz, 1 H), 3.82-3.74 (m, 3 H), 3.42 (t, J = 5.5 Hz, 2 H), 
3.30 (br s, 1 H), 2.82 (t, J = 4.5 Hz, 1 H), 2.69 (dd, J = 5.0, 2.5 Hz, 1 H), 1.57 (s, 6 H). 
13C NMR (DMSO-d6): δ 156.5, 156.0, 143.0, 142.4, 127.4 (2), 127.3 (2), 113.9 (2), 113.8 
(2), 69.9, 69.4, 68.8, 62.7, 49.7, 43.7, 41.1, 30.7 (2). MS (m/z) calc’d for C21H26O5 358.2, 
found 381.2 [M+Na]+. 
 
 
EPI-001. [REF. A1-A4] This compound was prepared by modification to the previously 
reported procedure [REF. A1]. To a stirred solution of 2 (0.164 g, 0.458 mmol) in CH3CN 
(10 mL) was added CeCl3 x 7H2O (0.427, 1.146 mmol) and mixture was heated to reflux 
for 12 h. The reaction was cooled to rt, excess CH2Cl2 was added to the white paste and 
the cerium salts were removed by filtration. The filtrate was concentrated in vacuo. The 
resulting crude material was purified by silica gel chromatography (gradient 50% EtOAc 
in CH2Cl2 to 100% EtOAc) to afford EPI-001 (0.117 g, 64% yield) as a clear foam. 1H 
NMR (DMSO-d6): δ 7.09 (dd, J = 8.5, 5.0 Hz, 4 H), 6.82 (t, J = 9.5 Hz, 4 H), 5.52 (d, J = 
5.5 Hz, 1 H), 4.90 (d, J = 5.0 Hz, 1 H), 4.63 (t, J = 5.5 Hz, 1 H), 4.02-3.99 (m, 1 H), 3.95-
3.92 (m, 3 H), 3.82-3.72 (m, 3 H), 3.65 (dd, J = 11.0, 5.0 Hz, 1 H), 3.42 (t, J = 6.0 Hz, 2 
H), 1.57 (s, 6 H)  13C NMR (DMSO-d6): δ 156.5, 156.1, 142.9, 142.4, 127.4 (2), 127.3 
(2), 113.9 (2), 113.8 (2), 69.9, 69.4, 68.8, 68.6, 62.7, 46.8, 41.1, 30.7 (2). MS (m/z) 
calc’d for C21H27ClO5 394.2, found 417.2 [M+Na]+. 
 
133 
 
Appendix Figure A1: Analysis of Purity of Synthesized EPI-001 and Commercial EPI-001 (Sigma-Aldrich). Analysis of purity of synthesized 
and commercial EPI-001 by reverse-phase HPLC. Solutions were monitored at 215 and 254 nm. Please see General section under Synthesis of 
EPI-001 for HPLC column and elution conditions. Two batches of EPI-001 were synthesized. (A) Batch 1 of synthesized EPI-001, which was 
utilized in this study. (B) Batch 2 of synthesized material. (C) Analysis of commercial EPI-001 (Sigma-Aldrich Product # 92427). (D) Co-injection of 
synthesized EPI-001 (from panel B) and commercial EPI-001 (panel C), which further demonstrates the compounds are identical. NOTE: 
Retention times for synthesized EPI-001, Batch 1 and Batch 2 (panels A and B) are slightly different because they were analyzed almost two years 
apart and HPLC column performances vary with use. 1H NMR spectra of batches 1 and 2 are identical. 
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Appendix Figure A2 (continues) 
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Appendix Figure A2 (Cont.) 
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Appendix Figure A2 (Cont.) 
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Supplementary Figure S2 (Cont.) 
 
 
Appendix Figure A2: NMR Spectra of Commercial EPI-001, Synthesized EPI-001 and 
Reaction Intermediates. 
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Appendix Figure A3 
 
 
 
Appendix Figure A3: Stability of EPI-001 Stock Solutions in DMSO and Ethanol. Analysis of 
purity of EPI-001 solutions prepared in either DMSO (panel A) or EtOH (panel B). Stock solutions 
were prepared by dissolving lyophilized drug in either EtOH or DMSO at a concentration of 100 
mM overnight at 4o C. Stocks were stored at 4o C for up to six months for use in experimentation. 
A substantial impurity was observed in the 254 nm channel for EPI-001 solutions prepared in 
EtOH. Following detection of the impurity, all stock solutions were prepared in DMSO and 
aliquoted for storage at -20o C to prevent decomposition. 
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